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“Há um tempo em que é preciso abandonar as roupas usadas, que já têm a forma do nosso 
corpo, e esquecer os nossos caminhos, que nos levam sempre aos mesmos lugares. É o 
tempo da travessia: e, se não ousarmos fazê-la, teremos ficado, para sempre, à margem de 
nós mesmos”. 
Fernando Pessoa 
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RESUMO 
Introdução: A espondilite anquilosante (EA) é uma doença inflamatória crónica 
caracterizada pela inflamação das articulações sacroilíacas e da coluna. A anquilose 
progressiva motiva uma deterioração gradual da função física e da qualidade de vida. O 
diagnóstico e o tratamento precoces podem contribuir para um melhor prognóstico. Neste 
contexto, a identificação de biomarcadores, assume-se como sendo muito útil para a prática 
clínica e representa hoje um grande desafio para a comunidade científica. 
Objetivos: Este estudo teve como objetivos: 1 - caracterizar a EA em Portugal; 2 - investigar 
possíveis associações entre genes, MHC e não-MHC, com a suscetibilidade e as 
características fenotípicas da EA; 3 - identificar genes candidatos associados a EA através da 
tecnologia de microarray. 
Material e Métodos: Foram recrutados doentes com EA, de acordo com os critérios 
modificados de Nova Iorque, nas consultas de Reumatologia dos diferentes hospitais 
participantes. Colecionaram-se dados demográficos, clínicos e radiológicos e colhidas 
amostras de sangue periférico. Selecionaram-se de forma aleatória, doentes HLA-B27 
positivos, os quais foram tipados em termos de HLA classe I e II por PCR-rSSOP. Os 
haplótipos HLA estendidos foram estimados pelo algoritmo Expectation Maximization com 
recurso ao software Arlequin v3.11. As variantes alélicas dos genes IL23R, ERAP1 e ANKH 
foram estudadas através de ensaios de discriminação alélica TaqMan. A análise de associação 
foi realizada utilizando testes da Cochrane-Armitage e de regressão linear, tal como 
implementado pelo PLINK, para variáveis qualitativas e quantitativas, respetivamente. O 
estudo de expressão génica foi realizado por Illumina HT-12 Whole-Genome Expression 
BeadChips. Os genes candidatos foram validados usando qPCR-based TaqMan Low Density 
Arrays (TLDAs). 
Resultados: Foram incluídos 369 doentes (62,3% do sexo masculino, com idade média de 
45,4 ± 13,2 anos, duração média da doença de 11,4 ± 10,5 anos). No momento da avaliação, 
49,9% tinham doença axial, 2,4% periférica, 40,9% mista e 7,1% entesopática. A uveíte 
anterior aguda (33,6%) foi a manifestação extra-articular mais comum. Foram positivos para 
o HLA-B27, 80,3% dos doentes. Os haplótipo A*02/B*27/Cw*02/DRB1*01/DQB1*05 parece 
conferir suscetibilidade para a EA, e o A*02/B*27/Cw*01/DRB1*08/DQB1*04 parece 
conferir proteção em termos de atividade, repercussão funcional e radiológica da doença. Três 
variantes (2 para IL23R e 1 para ERAP1) mostraram significativa associação com a doença, 
confirmando a associação destes genes com a EA na população Portuguesa. O mesmo não se 
verificou com as variantes estudadas do ANKH. Não se verificou associação entre as variantes 
génicas não-MHC e as manifestações clínicas da EA. Foi identificado um perfil de expressão 
génica para a EA, tendo sido validados catorze genes - alguns têm um papel bem 
documentado em termos de inflamação, outros no metabolismo da cartilagem e do osso.  
Conclusões: Foi estabelecido um perfil demográfico e clínico dos doentes com EA em 
Portugal. A identificação de variantes génicas e de um perfil de expressão contribuem para 
uma melhor compreensão da sua fisiopatologia e podem ser úteis para estabelecer modelos 
com relevância em termos de diagnóstico, prognóstico e orientação terapêutica dos doentes. 
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ABSTRACT 
Background: Ankylosing Spondylitis (AS) is a chronic inflammatory disorder characterized 
by inflammation in the spine and sacroiliac joints leading to progressive joint ankylosis and in 
progressive deterioration of physical function and quality of life. An early diagnosis and early 
therapy may contribute to a better prognosis. The identification of biomarkers would be 
helpful and represents a great challenge for the scientific community. 
Objectives: The present study had the following aims: 1- to characterize the pattern of AS in 
Portuguese patients; 2- to investigate MHC and non-MHC gene associations with 
susceptibility and phenotypic features of AS and; 3- to identify candidate genes associated 
with AS by means of whole-genome microarray. 
Material and Methods: AS was defined in accordance to the modified New York criteria 
and AS cases were recruited from hospital outcares patient clinics. Demographic and clinical 
data were recorded and blood samples collected. A random group of HLA-B27 positive 
patients and controls were selected and typed for HLA class I and II by PCR-rSSOP. The 
extended HLA haplotypes were estimated by Expectation Maximization Algorithm using 
Arlequin v3.11 software. Genotyping of IL23R, ERAP1 and ANKH allelic variants was 
carried out with TaqMan allelic discrimination assays. Association analysis was performed 
using the Cochrane-Armitage and linear regression tests as implemented in PLINK, for 
dichotomous and quantitative variables, respectively. Gene expression profile was carried out 
using Illumina HT-12 Whole-Genome Expression BeadChips and candidate genes were 
validated using qPCR-based TaqMan Low Density Arrays (TLDAs). 
Results: A total of 369 patients (62.3% male; mean age 45.4±13.2 years; mean disease 
duration 11.4±10.5 years), were included. Regarding clinical disease pattern, at the time of 
assessment, 49.9% had axial disease, 2.4% peripheral disease, 40.9% mixed disease and 7.1% 
isolated enthesopathic disease. Acute anterior uveitis (33.6%) was the most common extra-
articular manifestation. 80.3% of AS patients were HLA-B27 positive. The haplotype 
A*02/B*27/Cw*02/DRB1*01/DQB1*05 seems to confer susceptibility to AS, whereas 
A*02/B*27/Cw*01/DRB1*08/DQB1*04 seems to provide protection in terms of disease 
activity, functional and radiological repercussion. Three markers (two for IL23R and one for 
ERAP1) showed significant single-locus disease associations. Association of these genes with 
AS in the Portuguese population was confirmed, whereas ANKH markers studied did not 
show an association with AS. No association was seen between non-MHC genes and clinical 
manifestations of AS. A gene expression signature for AS was established; among the 
fourteen validated genes, a number of them have a well-documented inflammatory role or in 
modulation of cartilage and bone metabolism.  
Conclusions: A demographic and clinical profile of patients with AS in Portugal was 
established. Identification of genetic variants of target genes as well as gene expression 
signatures could provide a better understanding of AS pathophysiology and could be useful to 
establish models with relevance in terms of susceptibility, prognosis, and potential therapeutic 
guidance.
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1. INTRODUCTION 
Ankylosing spondylitis (AS) is the prototypic disease of a group of arthropathies called 
seronegative spondyloarthritis (SpA). It represents a group of related conditions that also 
includes arthritis associated with inflammatory bowel disease (IBD), psoriatic arthritis, 
arthritis associated with acute anterior uveitis (AAU), reactive arthritis, and undifferentiated 
SpA (uSpA) [Rudwaleit et al., 2009a; 2010]. Collectively, all these conditions have a 
common background of inflammatory arthritis (predisposition to axial arthritis involving the 
spine and sacroiliac joints but also peripheral arthritis), extra-articular inflammation, 
seronegativity for rheumatoid factor and a strong HLA-B27 association [Dougados et 
al.,1991; Calin & Taurog, 1998]. Inflammatory back pain is a characteristic symptom; new 
bone formation with syndesmophytes and ankylosis, are the disease radiographic hallmark. 
Histopathologically, AS is characterized by the presence of enthesis inflammation [Benjamin 
& McGonagle, 2001]. 
The incidence and prevalence rates mirror the prevalence of HLA-B27 seropositivity [Khan, 
1996] which in turn has a strong population variation. In fact, among adults who are positive 
for the presence of HLA-B27, the prevalence of all types of SpA and AS in particular, were 
estimated at 4.5% and at 1.6%, respectively [Benevolenskaya et al., 1996]. As far as ethnicity 
is concerned, 8% of Caucasians were found to be HLA-B27 positive, and to have a prevalence 
of SpA up to 1.3% and of AS ranging from 0.2% to 0.9% [Braun et al., 1998]. The 
Portuguese available data comes from a random sample of 1238 people (age > 18 years old) 
drawn from the Oporto population; in this study a standard questionnaire was used to 
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ascertain self-reported AS information (albeit one should note this information was not 
validated by any clinician). In this survey, AS prevalence was estimated at 0.6% [ONDoR, 
2003-2005]. In addition, in Terceira Island SPA was found to have a prevalence of 1.6% in 
people over 50 years old [Bruges-Armas et al., 2002]. SpA and AS are, therefore amongst the 
most common forms of inflammatory arthritis. 
The incidence of AS has already studied in different populations and some discrepancies were 
found. Similar ratios of 6.4, 6.9, 7.26 and 7.3 per 100,000 people per year were estimated in 
populations in Czech Republic [Hanova et al., 2010], Finland [Kaipiainen-Seppanenet et al., 
1997], Norway [Bakland et al., 2005] and Rochester - USA [Carbone et al., 2005], 
respectively. However, in other populations, such as Greek, the incidence of AS seems to be 
significantly lower - 1.5 per 100,000 [Alamanos et al., 2002]. In fact, many challenging 
factors have made it difficult to determine the exact prevalence and incidence of SpA. Among 
these, population ethnic heterogeneity, lack of feasibility to apply current criteria, and the 
transient nature of some SpA symptoms (peripheral arthritis and enthesitis) are to be included 
[Reveille, 2011]. Nevertheless, in the past few years some general fixed traits in 
epidemiologic characteristics of AS seem to emerge [Gabriel & Michaud, 2009]. The 
incidence of AS appears to be relatively stable over time [Kaipiainen-Seppanen et al., 1997; 
Bakland et al., 2005] or even with a tendency to decline [Bakland et al., 2005]. 
AS typically affects young people; 80% of the patients develop the first symptoms at an age 
younger than 30 years, and less than 5% older than 45 years [Feldtkeller et al., 2003]. Men 
are more often affected than women, with a ratio of roughly 2:1 [Brunner et al., 2002; 
Feldtkeller et al., 2003]. Some authors have even described higher ratios of 3:1 [Lee et al., 
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2007] or even of 6-8:1 in some Asian populations [Lee et al., 2002; Zeng et al., 2003; Jung et 
al., 2010]. The reasons for such gender disparities haven’t established yet. 
Clinical features include inflammatory back pain, asymmetrical peripheral oligoarthritis 
(predominantly of the lower limbs), enthesitis, and specific organ involvement such as AAU, 
psoriasis, and chronic inflammatory bowel disease. Pulmonary, renal, neurological, aortic root 
involvement and conduction abnormalities are all rare complications of AS [Braun & Sieper, 
2007]. However, in accordance to studies performed in European and Asian populations, 
patients with AS have a higher prevalence of multiple comorbidities than general population 
[Bremander et al., 2011]. In Taiwanese AS cases, it was documented that there was an 
increased risk for cardiovascular, neurological, pulmonary, gastrointestinal, endocrine, 
haematological and mental illnesses. Hypertension (16.4%), peptic ulcers (13.9%) and 
headaches (10.2%) were the most prevalent findings [Kang et al., 2010]. The increased risk 
for cardiovascular disease in AS is a consistent finding mentioned in several studies. It is 
probably multifactorial, being related both to chronic systemic inflammation and to high 
prevalence of conventional cardiovascular risk factors [Boonen et al., 2002; Mathieu et al., 
2010; Bakland et al., 2011]. Moreover, AS also increases mortality by 50% when compared 
with age- and gender- matched controls [Boonen et al., 2002]. Interestingly, standardised 
mortality rates seem to be significantly increased only among male patients compared with 
female patients [Bakland et al., 2011]. Finally, male patients seem to have more structural 
changes, including bamboo spine, low bone density [Karberg et al., 2005], and an increased 
rate of fractures [Cooper et al., 1994] which may also contribute to hyperkyphosis [Vosse et 
al., 2006], in comparison with female patients. Taken together, articular and systemic 
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involvement, need to be concurrently and comprehensively studied to evaluate the total 
burden of this rheumatic disease both in terms of individual and societal impact.  
In this context, many studies have reported that AS leads to deterioration of physical function 
and deterioration of health-related quality of life (HRQoL), with repercussions in terms of 
work disability and in increasing demand of health care services. The best means to 
understand the burden of the disease in a specific population is to compare it with the general 
population [Ware, 2000]. Generic measures, such as the Short Form (36 item) Health Survey 
(SF-36), allow this kind of comparisons, contrary to disease-specific HRQoL measures 
[Guyatt et al., 1993]. Studies that compared HRQoL of AS patients with general population 
reported significantly low HRQoL on physical and a less extent on psychosocial domains, 
when raw scores [Dagfinrud et al., 2004] or age-sex-adjusted scores were considered [Davis 
et al., 2005; Singh & Strand, 2009]. Thus, it means that physical component may be the main 
contributor to morbility associated to this condition. Many of the following factors may 
influence HRQoL: severity and disease duration; response to current therapy; treatment-
related adverse events; medical comorbility; socioeconomic factors; and healthcare access. 
However, as many of these factors may be changed, targeted interventions may also 
potentially improve function and HRQoL in these patients [Singh & Strand, 2009]. In the 
other hand, some prognostic factors linked to functional repercussion were identified. The 
onset of symptoms at a young age yields the worse functional outcomes [Stone et al., 2005]. 
Additionally, in patients with a disease longstanding of 20 years, functional restrictions are 
worse in those with a history of physically demanding jobs, more comorbid conditions, and in 
smokers, than in those with higher levels of education and a family history of AS [Ward, 
2005].  
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These considerations might also partially explain the high levels of work disability and the 
negative impact on productivity and social costs [Boonen et al., 2002]. In Dutch patients with 
AS, it has been shown that labour force participation was 11% lower and AS related work 
disability 15% higher than in general population. In those with a paid job, the mean number of 
AS related sick leave days per patient was 10 days per year [Boonen et al., 2001]. In terms of 
health care services demand results from some European studies have reported a range 
between 1.4 - 4.0 for general consultations and 1.7 - 2.8 for specialist consultations per year 
incurred by AS patients [Boonen et al., 2003a, 2003b, 2005; Verstappen et al., 2007]. Similar 
results were obtained from a USA cohort with values higher than 2.1 for outpatient generalist 
and specialist visits [Ward, 2002]. Based on administrative databases, two previous studies 
from Canada [Kobelt et al., 2006] and Germany [Zink et al., 2006] reported 16-18 visits to a 
generalist and 3.7-4.2 visits to a rheumatologist annually. Health care delivery systems, 
countries, studied cohorts, patient characteristics (including presence of medical 
comorbidities and disease severity) and the method for ascertaining health care demand may 
explain these differences. However all studies documented an increase in health care services 
demand. Many possible reasons can be pointed out in order to explain this increase: 
a) Primary care need is associated with symptoms directly related with SpA/AS 
(back pain, joint pain, enthesitis) and/or presence or severity of other comorbid 
conditions and/or treatment-related complications;  
b) Surgical clinic need is related to SpA consequences (e.g. hip or knee 
arthroplasty) and/or related to associated comorbidities; 
c) Specific rheumatology visits are likely to reflect regular follow-up to 
rheumatology clinic for treatment of SpA and the monitoring of these therapies;  
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d) Other specialty clinics, like gastroenterology, nephrology and cardiology, for 
SpA/AS or therapeutic associated complications. 
It is also important to analyse AS impact in terms of costs. Annual total costs averaged US$ 
6,720 (in 1999, median US$ 1,495). Indirect costs comprised 73.6% and direct costs 
comprised 26.4% of total costs, although only 39% of patients contributed to indirect costs 
[Ward, 2002]. Functional disability was the most important predictor of high total costs. 
Likelihood of having high (>US$ 10,000) total costs increased by a factor of three with each 
single-point increase in Health Assessment Questionnaire disability index modified for the 
SpA (HAQ-S; range 0–3) [Ward, 2002]. In one study conducted in Portugal, a statiscally 
significant correlation between total cost (supported by the patient) and BASDAI and HAQ 
was observed [Miranda et al., 2008]. Therefore, interventions that maintain or improve 
patients’ functional ability will likely have the greatest potential to decrease the costs of AS. 
Likewise, comorbidities might also influence costs. However, further studies are needed to 
examine the association between increased financial stress upon health care services and 
comorbidities (both in number and severity); further, it should be also analysed whether a 
better control of comorbidities reduces health costs in SpA patients. Keen attention should be 
given to results interpretation of such studies as costs may vary internationally, depending on 
each country health care system [Boonen et al., 2002]. 
All factors considered together (disease prevalence, likely irreversibility of progressive 
ankylosis in affected joints, comorbidities, and socioeconomic impact of disease), it is 
reasonable to suggest that early diagnosis and effective treatment offer the best chances of 
improving prognosis; this approach stands for the present paradigm shift.  
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Several studies have shown a delay of more than eight years between the onset of symptoms 
and diagnosis, with consequent delay in starting therapy [Feldtkeller et al., 2003]. This is a 
critical period for clinical damage.  
The modified New York criteria [van der Linden et al., 1984], requires the presence of 
radiographic sacroiliitis for diagnosis purposes. This is a major concern because it has been 
estimated that after the onset of inflammation in SI joints, a period of six to eight years must 
elapse before sacroiliitis can be detected on plain radiographs [Rudwaleit et al., 2005, 2009b; 
Bennettet et al., 2008]. Although the proportion of SpA that evolves to AS is unknown, 
patients with non-radiographic axial SpA have the same high disease activity as patients with 
established AS in terms of signs and symptoms [Rudwaleit et al., 2009b]. For this reason, 
some authors have hypothesised that patients with non-radiographic axial SpA and patients 
with established AS display different stages of a single disease continuum and, therefore, the 
same disease entity [Rudwaleit et al., 2005]. Assuming this hypothesis to be true, the new 
ASAS criteria for axial SpA may allow the identification of early stages of disease, when 
radiographic sacroiliitis is still abstent. 
To assess the efficacy of therapeutical agents, BASDAI 50 [Braun et al., 2003] and ASAS 
improvement criteria [Anderson et al., 2001] were proposed. It is still unclear whether the 
changes highlighted by these scores are helpful in patient monitoring. The recently introduced 
ASDAS seems to be a highly discriminatory instrument for assessing disease activity in AS 
and therapeutic response [Lukas et al. 2009; van der Heijde et al., 2009; Machado et al., 
2011]. ASDAS is unquestionably of potential usefulness in clinical practice, even if it wasn’t 
initially developed as a predictor of response to therapy. As a matter of fact, and in order to 
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have some insight into response to therapy, some markers were identified as positive therapy 
responsiveness, namely: younger age, HLA-B27 carriage, elevation of acute phase reactants 
(CRP), and marked spinal inflammation (detectable by MRI). Likewise, other factors were 
identified as negative markers of therapy response: older age, structural damage and poor 
function may be predictors of poor- or non-responsiveness [Rudwaleit et al., 2004, 2008]. 
Although all these markers were found to be of interest due to their statistical significance, 
each patient is a case of its own and therefore new and more discriminative biomarkers are 
needed for clinical purposes. The need to personalize treatment is further accentuated by 
economical reasons; the introduction of anti-TNF alpha drugs (infliximab, etanercept, 
adalimumab, golimumab) and the expectation of new therapies for different targets are 
extremely expensive and unbearable by public health systems. In such a context, therapy 
selection will become an issue and new powerful biomarkers are needed to ensure both 
correct monitoring of disease and correct and meaningful drug selection and use. 
Identification of relevant markers for diagnosis, prognosis, and treatment response will render 
an easier diagnosis and also allow the best choice of treatment, based on therapy likelihood to 
elicit a positive response. This would have the extra advantage of significantly reducing 
treatment costs by minimizing the use of expensive therapeutic agents in patients unlikely to 
respond to them. 
In recent years, improvements in genotyping and in study design have had a major impact in 
AS. New findings provide fascinating insights into the pathogenesis of the disease and offer 
new potential therapeutic targets [Brown et al., 2010; Evans et al., 2011]. Moreover, two 
recent studies showed that anti-TNF alpha treatment leads to significant alteration of gene 
expression and in proteomic profiling; the authors’ data support the use of systematic gene 
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expression and proteomic analysis to shed new light on pathogenic pathways in chronic 
inflammation of AS and eventually in therapeutic response [Visvanathan et al., 2008; Haroon 
et al., 2010]. Such findings raise expectations that genetic studies can aid in the development 
of more discriminating diagnostic methods and the current project is a natural extension of all 
these recent discoveries. 
The specific aim of the current study is to characterize the clinical AS pattern in Portugal and 
to assess genetic predictors of susceptibility to AS. It was hypothesized that genetic factors 
may predict the susceptibility to the disease. Additionally, genetic factors may also contribute 
to predict the prognosis and clinical response to different therapies used.  
The aims of the present study are: 
a)  To collect a representative sample of AS Portuguese patients to characterize the 
disease (epidemiologically and clinically) in Portugal;  
b) To validate the instruments used currently in clinical practice - the Bath AS indices - 
to Portuguese;  
c) To create new tools to monitor AS; 
d) To contribute to the identification of biomarkers with potential interest for diagnosis 
(and secondary for clinical response to therapy and prognosis) in AS patients.  
 
The present research project led to the creation of a work group called CORPOREA - 
COnhecer a Realidade Portuguesa sobre Espondilite Anquilosante [Portuguese Ankylosing 
Spondylitis Knowledge Group]. Many different national, Rheumatology and Physiatry 
Centres, took part in this work Group namely: Centro Hospitalar de Lisboa Ocidental, 
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Hospital de Egas Moniz EPE, Lisboa; Centro Hospitalar de Lisboa Norte, Hospital de Santa 
Maria EPE, Lisboa; Instituto Português de Reumatologia, Lisboa; Hospital Militar Principal, 
Lisboa; Hospital Curry Cabral EPE; Hospital Garcia de Orta EPE, Almada; Centro Hospitalar 
do Alto Minho, Hospital Conde de Bertiandos EPE, Ponte de Lima; Hospital de São Marcos, 
Braga; Hospital de Faro EPE, Faro; Centro Hospitalar Baixo Vouga, Hospital Infante D. 
Pedro EPE, Aveiro; Centro Hospitalar Oeste Norte, Centro Hospitalar das Caldas da Rainha 
EPE, Caldas da Rainha. To reduce bias related to recruitment, patients from Azores and 
Madeira were not included in the present study. Several national (Institute of Molecular 
Medicine, Faculty of Medicine, University of Lisbon) and international (University of 
Queensland, Brisbane, Australia; Institut Cochin, Department of Immunology and INSERM, 
Paris, France), partnerships have been established to bring out necessary conditions for 
completion of all topics of this project.  
By involving multiple national centres, a country dimension was granted to the project. 
During 6 months, a Rheumatology team from Hospital de Egas Moniz went out to interview, 
assess, and collect biological samples from patients recruited at each enroled centre. A 
convenient sample of 369 patients was obtained according to the following criteria:  
a) Inclusion criteria- Patients that fulfill the modified New York diagnostic 
criteria for AS; Age ≥ 18 years old; Portuguese ancestry until the second 
generation; expression of agreement under informed consente to participate in 
this research project.  
b) Exclusion criteria- Other inflammatory disease besides AS; Age < 18 years 
old; refusal of participation; unability to give informed consent. 
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Biological samples from healthy individuals were collected as a control group. Some samples 
from the National bone marrow donors’ database of Centro de Histocompatibilidade do Sul 
were also randomly selected. 
This research project received favorable evaluation of the Centro Hospitalar de Lisboa 
Ocidental Ethics Committee and from all Hospitals involved.  
The present work is organized in three chapters. Each one of them reflects different stages of 
research:  
a) Chapter I, is on clinical nature. It reports the characterization of Portuguese patients 
with AS. Bath indices validated to Portuguese are disclosed. Finally, normative charts 
for BASDAI, BASFI, BASMI, and mSASSS for both genders are reported.  
b) Chapter II, is based on genetic DNA studies. There, one can find a report of 
experiments performed to ascertain validity of several candidate genes in the 
Portuguese population (and to find variants associated with disease 
susceptibility/severity).  
c) Chapter III, is based on genetic RNA studies where microarray technology was used to 
identify new candidate genes associated with disease susceptibility. 
SCIENTIFIC RESEARCH 
 
 
15 
 
2. SCIENTIFIC RESEARCH 
2.1. CLINICAL RESEARCH  
2.1.1. Validation of Bath indices in Portuguese  
Pimentel-Santos FM, Pinto LT, Santos H, Barcelos A, Cunha I, Branco JC, Ferreira PL. 
Portuguese version of the bath indexes for ankylosing spondylitis patients: a cross-
cultural adaptation and validation. Clin Rheumatol. 2012 Feb; 31(2): 341-6. 
 
 
 
 
 
 
 
 
SCIENTIFIC RESEARCH 
 
 
16 
 
 
SCIENTIFIC RESEARCH 
 
 
17 
 
 
SCIENTIFIC RESEARCH 
 
 
18 
 
 
SCIENTIFIC RESEARCH 
 
 
19 
 
 
SCIENTIFIC RESEARCH 
 
 
20 
 
 
SCIENTIFIC RESEARCH 
 
 
21 
 
SCIENTIFIC RESEARCH 
 
 
22 
 
2.1.2. Clinical and epidemiological characterization of Ankylosing Spondylitis in 
Portugal 
 
Pimentel-Santos FM, Mourão AF, Ribeiro C, Costa J, Santos H, Barcelos A, Pinto P, 
Godinho F, Cruz M, Sousa E, Santos RA, Rabiais S, Félix J, Fonseca JE, Guedes-Pinto H, 
Brown MA, Branco JC and CORPOREA Study Group. Spectrum of ankylosing spondylitis 
in Portugal. Development of BASDAI, BASFI, BASMI and mSASSS reference centile 
charts. Clin Rheumatol. 2012 Mar; 31(3): 447-54. 
 
 
 
 
 
 
 
 
SCIENTIFIC RESEARCH 
 
 
23 
 
 
SCIENTIFIC RESEARCH 
 
 
24 
 
 
SCIENTIFIC RESEARCH 
 
 
25 
 
 
SCIENTIFIC RESEARCH 
 
 
26 
 
 
SCIENTIFIC RESEARCH 
 
 
27 
 
 
SCIENTIFIC RESEARCH 
 
 
28 
 
 
SCIENTIFIC RESEARCH 
 
 
29 
 
 
SCIENTIFIC RESEARCH 
 
 
30 
 
 
SCIENTIFIC RESEARCH 
 
 
31 
 
 
2.2. GENETIC DNA BASED STUDIES 
2.2.1. State of the art in genetics of Ankylosing Spondylitis in 2007 
Santos FP, Bastos E, Ligeiro D, Mourão AF, Chaves R, Trindade H, Guedes-Pinto H, Branco 
JC. Genetic basis of ankylosing spondylitis. Acta Reumatol Port. 2007 Jul-Sep; 32(3): 243-
52. 
 
 
SCIENTIFIC RESEARCH 
 
 
32 
 
 
SCIENTIFIC RESEARCH 
 
 
33 
 
  
SCIENTIFIC RESEARCH 
 
 
34 
 
 
SCIENTIFIC RESEARCH 
 
 
35 
 
 
SCIENTIFIC RESEARCH 
 
 
36 
 
 
SCIENTIFIC RESEARCH 
 
 
37 
 
 
SCIENTIFIC RESEARCH 
 
 
38 
 
 
SCIENTIFIC RESEARCH 
 
 
39 
 
 
SCIENTIFIC RESEARCH 
 
 
40 
 
 
SCIENTIFIC RESEARCH 
 
 
41 
 
SCIENTIFIC RESEARCH 
 
 
42 
 
 
2.2.2. Studies of MHC genes  
2.2.2.1. HLA class I and II  
Pimentel-Santos FM, Matos M, Ligeiro D, Mourão AF, Ribeiro C, Costa J, Santos H, 
Barcelos A, Pinto P, Godinho F, Cruz M, Sousa E, Santos RA, Fonseca JE, Trindade H, 
Guedes-Pinto H, Brown MA, Branco JC and CORPOREA Study Group. HLA Class I and II 
Associations of Ankylosing Spondylitis. (submitted to J Rheumatol) 
 
SCIENTIFIC RESEARCH 
 
 
43 
 
 
SCIENTIFIC RESEARCH 
 
 
44 
 
 
SCIENTIFIC RESEARCH 
 
 
45 
 
 
SCIENTIFIC RESEARCH 
 
 
46 
 
 
SCIENTIFIC RESEARCH 
 
 
47 
 
 
SCIENTIFIC RESEARCH 
 
 
48 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SCIENTIFIC RESEARCH 
 
 
49 
 
 
SCIENTIFIC RESEARCH 
 
 
50 
 
 
SCIENTIFIC RESEARCH 
 
 
51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SCIENTIFIC RESEARCH 
 
 
52 
 
 
SCIENTIFIC RESEARCH 
 
 
53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SCIENTIFIC RESEARCH 
 
 
54 
 
 
SCIENTIFIC RESEARCH 
 
 
55 
 
 
SCIENTIFIC RESEARCH 
 
 
56 
 
 
SCIENTIFIC RESEARCH 
 
 
57 
 
 
SCIENTIFIC RESEARCH 
 
 
58 
 
 
SCIENTIFIC RESEARCH 
 
 
59 
 
 
SCIENTIFIC RESEARCH 
 
 
60 
 
 
SCIENTIFIC RESEARCH 
 
 
61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SCIENTIFIC RESEARCH 
 
 
62 
 
 
SCIENTIFIC RESEARCH 
 
 
63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SCIENTIFIC RESEARCH 
 
 
64 
 
 
SCIENTIFIC RESEARCH 
 
 
65 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SCIENTIFIC RESEARCH 
 
 
66 
 
 
SCIENTIFIC RESEARCH 
 
 
67 
 
 
SCIENTIFIC RESEARCH 
 
 
68 
 
 
SCIENTIFIC RESEARCH 
 
 
69 
 
 
SCIENTIFIC RESEARCH 
 
 
70 
 
 
SCIENTIFIC RESEARCH 
 
 
71 
 
 
SCIENTIFIC RESEARCH 
 
 
72 
 
 
SCIENTIFIC RESEARCH 
 
 
73 
 
 
SCIENTIFIC RESEARCH 
 
 
74 
 
 
SCIENTIFIC RESEARCH 
 
 
75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SCIENTIFIC RESEARCH 
 
 
76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SCIENTIFIC RESEARCH 
 
 
77 
 
 
SCIENTIFIC RESEARCH 
 
 
78 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SCIENTIFIC RESEARCH 
 
 
79 
 
2.2.2.2. HLA class III 
Sousa E, Caetano-Lopes J, Pinto P, Pimentel F, Teles J, Canhão H, Rodrigues A, Resende C, 
Mourão AF, Ribeiro C, Pinto TL, Rosa CM, da Silva JA, Branco J, Ventura F, Queiroz MV, 
Fonseca JE. Ankylosing spondylitis susceptibility and severity--contribution of TNF gene 
promoter polymorphisms at positions -238 and -308. Ann N Y Acad Sci. 2009 Sep; 1173: 
581-8.  
 
SCIENTIFIC RESEARCH 
 
 
80 
 
 
SCIENTIFIC RESEARCH 
 
 
81 
 
 
SCIENTIFIC RESEARCH 
 
 
82 
 
 
SCIENTIFIC RESEARCH 
 
 
83 
 
 
SCIENTIFIC RESEARCH 
 
 
84 
 
 
SCIENTIFIC RESEARCH 
 
 
85 
 
 
SCIENTIFIC RESEARCH 
 
 
86 
 
 
SCIENTIFIC RESEARCH 
 
 
87 
 
SCIENTIFIC RESEARCH 
 
 
88 
 
 
2.2.3. Studies of non-MHC genes  
2.2.3.1. ERAP1 and IL23R 
Pimentel-Santos FM, Ligeiro D, Matos M, Mourão AF, Sousa E, Pinto P, Ribeiro A, Sousa 
M, Barcelos A, Godinho F, Cruz M, Fonseca JE, Guedes-Pinto H, Trindade H, Evans DM, 
Brown MA, Branco JC. Association of IL23R and ERAP1 genes with ankylosing 
spondylitis in a Portuguese population. Clin Exp Rheumatol. 2009 Sep-Oct; 27(5): 800-6. 
 
SCIENTIFIC RESEARCH 
 
 
89 
 
 
SCIENTIFIC RESEARCH 
 
 
90 
 
 
SCIENTIFIC RESEARCH 
 
 
91 
 
 
SCIENTIFIC RESEARCH 
 
 
92 
 
 
SCIENTIFIC RESEARCH 
 
 
93 
 
 
SCIENTIFIC RESEARCH 
 
 
94 
 
 
SCIENTIFIC RESEARCH 
 
 
95 
 
SCIENTIFIC RESEARCH 
 
 
96 
 
2.2.3.2. ANKH 
Pimentel-Santos FM, Ligeiro D, Matos M, Mourão AF, Sousa EV, Pinto P, Ribeiro A, Santos 
H, Barcelos A, Godinho F, Cruz M, Fonseca JE, Guedes-Pinto H, Trindade H, Brown MA, 
Branco JC and CORPOREA Study Group. ANKH and Susceptibility to and Severity of 
Ankylosing Spondylitis. J Rheumatol. 2012 Jan; 39: 131-4. 
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2.2.3.3. TNFSF8 
Zinovieva E, Kadi A, Letourneur F, Cagnard N, Izac B, Vigier A, Said-Nahal R,  
Elewaut D, de Vlam K, Pimentel-Santos F, Chiocchia G, Breban M. Systematic 
candidate-gene investigations in the SPA2 locus (9q32) show an association 
between the gene TNFSF8 and susceptibility to spondyloarthritis. Arthritis Rheum. 2011 
Jul; 63(7): 1853-9. 
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2.3. GENE EXPRESSION STUDIES  
2.3.1. Brief review on Microarray technology 
 
Recent advances in molecular biology, in particular, the completion of the genome human 
sequence, the improvement in computational tools and the rapid access to large databases, 
allow an integrated understanding of biological systems, through “omic” approaches. The 
main challenge, however, is to extract relevant knowledge from the huge amount of data 
provided by these technologies for the development of biomarkers for diagnosis, prognosis, 
therapy monitoring and both prediction and monitoring of treatment response. Such 
technological advances represent the beginning of patient-specific personalized medicine 
[Kandpal et al., 2009].  
In contrast to traditional DNA-based diagnostic tests that largely focus on single genes 
associated with rare conditions, microarray-based genotyping and expression assays are ideal 
for the study of diseases with underlying complex genetic causes [Li et al., 2008]. Microarray 
gene expression technology can be used for the detection and quantification of differentially 
expressed genes. Its ability to study expression of several thousand genes or even all of the 
genes of the entire genome in a single experiment has changed biomedical research. Gene-
expression profiling confers a “snapshot” of cellular activity providing information on the 
mechanisms mediating stress responses of human cells [Belcher et al., 2000; Guillemin et al., 
2002], identification of signaling cascades [Shaffer et al., 2000; Diehn et al., 2002], disease 
changes, or mechanisms underlying therapy responses [Raetz & Moos, 2004]. It represents an 
advance to the traditional molecular genomic techniques that have been previously applied in 
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broad clinical research fields as cancer, infection diseases, metabolic diseases, genetics and 
more recently, in rheumatic diseases. 
 
2.3.1.1. Microarray fundamentals 
Gene expression techniques, based on measuring mRNA levels, have greatly evolved since 
the development of the Northern blot, in 1975 [Southern, 1975] to microarrays, in the mid 
1990s [Shalon et al., 1996]. From a single labeled mRNA (probe), hybridized on a membrane 
(Northern Blot), to multiple probes hybridized on a membrane (macroarrays) or on glass 
(microarrays), the improvement was tremendous. Today several platforms, with pre-designed 
and custom arrays are available in the market [Hardiman, 2004] from commercial suppliers 
including Affymetrix, Agilent and Illumina. Table 1 summarizes similarities and differences 
between the most widely used platforms. 
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Table 1: Microarray platforms comparison. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Platforms 
 Affymetrix Agilent Illumina 
Array format 25-mer 60-mer 50-mer 
Starting RNA requirement 5μg total RNA 
Fluorescent Direct 
Label Kit (cDNA 
labeling): 10μg total 
RNA, or 200ng 
polyA+ RNA 
Low input RNA 
Fluorescent Linear 
Amplification kit 
(Amplified cDNA 
labeling): 50ng total 
RNA 
Low input RNA  
Fluorescent Linear 
Amplification kit 
(Amplified cRNA 
labeling): 50ng total 
RNA 
 
50-500ng total RNA 
Hybridization time 16h 
Fluorescent Direct 
Label Kit: 3-4 hours 
Low input RNA 
Fluorescent Linear 
Amplification kit 
Amplified cDNA 
labeling: 10 hours 
Amplified cRNA 
labeling: 6 hours 
16h 
Hybridization temperature 45ºC 60ºC 55ºC 
Detection method 
Streptavidin-
phycoerythrin 
Cyanine 3 (Cy3) and 
cyanine 5 (Cy5) 
Fluorescent labeling  
Streptavidin-Cy3 
 
Advantages 
Reproducibility;  Full 
genome coverage; 
mature platform; 
customization 
More probes per gene 
Reproducibility; 
content; mature 
platform; sensitivity; 
customization 
Reproducibility; Full 
genome coverage 
Sensitivity 
Low background 
Mature platform 
Low cost/sample 
Low starting material 
required 
Disadvantages 
Short 
oligonucleotides-less 
sensitive 
High cost/sample 
Two-color dye bias 
and ozone-related 
degradation 
Currently only available for 
human, rat and  mouse 
studies 
Fewer probes per gene, not 
so sensitive to detect splice 
variants. 
SCIENTIFIC RESEARCH 
 
 
112 
 
Despite minor differences between platforms, the basic steps involved in a microarrays 
experiment are similar (Fig. 1) [Repsilber et al., 2005]. Key points in undertaking an 
expression profiling study are; 
a) Establish your research question which will influence 
b) Selection of the tissue/cell most relevant to the question and the selection of the 
control group 
c) Total mRNA is extracted from the chosen tissue/cell, and reverse transcribed 
generating cDNA which is labeled with radioactive or fluorescent markers 
d) Labeled transcripts are hybridized onto the microarray 
e) Bound probes are detected and quantified by imaging tools and every gene/probe 
assigned a signal intensity 
f) Signals are corrected for common bias i.e. normalized. For each mRNA, the signal 
intensity difference between the disease and the control sample correlates to the 
change in gene expression (genes up- or down-regulated) that might be associated 
with the studied condition. Several methods have been implemented to reduce 
variability in DNA microarray experiments [Workman et al., 2002]. A critical step 
in the whole procedure is an appropriate analysis of the large volumes of data 
generated using sophisticated software. Bioconductor (www.bioconductor.org) or 
BRB ArrayTools [Simon et al., 2007], examples of bioinformatics’ platforms, 
provide tools for analysis and comprehension of genomic data. 
g) Candidate genes are validated through another technology. Usually quantitative 
reverse-transcription PCR (qPCR) is the preferred method 
h) Data is integrated and applied to the initial question.  
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2.3.1.2. Microarray challenges and concerns 
 
Large-scale gene expression analysis, is in fact, a flourishing technology with potential 
applications in several fields of Biology and Medicine as indicated by the large number of 
peer-reviewed articles (n=35502) containing the words “gene” and “microarray” found in 
“Pubmed” up to June 2011.  
Microarray profiling of gene expression is a powerful tool for discovery, but the ability to 
manage and compare the resulting data can be problematic. Biological, experimental, and 
technical variations between studies of the same phenotype/phenomena create substantial 
differences in results. Some of these issues will be discussed in detail. 
a) The success of the microarray experience greatly depends on whether the 
hypothesis and rationale have been appropriately formulated through a clearly 
delineated question. It influences the study design as a whole, from sample collection, 
to experimental design and finally, the strategies for data analysis [Smith & Rosa, 
2007]. 
b) While most of the early studies used primary tissues involved in the disease, 
such as tumor biopsies, more recently a number of gene expression profiling studies 
have focused on peripheral blood to identify systemic markers of disease. However, 
gene expression patterns in peripheral blood cells greatly depend on inter-individual 
variations and technical aspects such as blood sampling techniques, cell and RNA 
isolation as well as storage temperature or delays in processing. However although 
significant inter-individual variations on gene expression patterns in peripheral blood 
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cells can be seen, these differences are often much less than the differences between 
blood samples from healthy donors and from patients. These observations and the 
accessibility of peripheral blood, strongly suggests that gene expression analysis of 
peripheral blood is probably the best source for the assessment of systemic differences 
or changes in gene expression associated with disease or drug response [Debey et al., 
2004].  
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Design, experimental and data analysis steps in a typical microarray gene expression 
experiment. (Adapted from Repsilber et al., 2005). 
 
 
c) Appropriate experimental design is another critical step for the success of a 
microarray experiment. It’s important to control and exclude as many biases as 
possible [Ransohoff, 2007]. Integrity and purity of RNA extracted, cDNA labeling and 
hybridization procedures may affect reproducibility, and thus these steps need to be 
standardized and optimized. However, several key issues regarding appropriate 
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replication remains in discussion: the minimum sample size, the necessity of running 
multiple arrays with the same samples or the potential benefits and risks associated 
with pooling samples [Smith & Rosa, 2007]. Increasing the sample size will lower the 
false discovery and false negative rates but it represents an expensive option [Pawitan 
et al., 2005]. Given the well-established reproducibility of commercially available 
platforms, technical replication is not required currently. Finally, pooling samples can 
reduce the variation between arrays but potential outliers may get masked or may 
compromise the entire pool [Smith & Rosa, 2007]. To guaranty an improvement of 
data quality, replication studies in independent patient series must be performed, but 
these analyses are often lacking [Ionnidis et al., 2009].  
d) Data analysis currently represents a major challenge for researchers. A closer 
look at the literature reveals many conflicting results. A consensus regarding strategies 
in data analysis is required. In the last years some papers have reviewed in detail how 
to analyze typical microarray data experiments [Allison et al., 2006; Reimers, 2010], 
to interpret them [Michiels et al., 2007] and to report the results [Dupuy & Simon, 
2007]. The multidimensionality of microarrays and possible solutions to deal with this 
issue is well discussed in a recent review [Michiels et al., 2011]. 
e) Confirmation and validation studies are another crucial step. For confirmation 
studies the initial results must be reproduced using another assay technology, usually 
qPCR. Validation studies require an independent study in a new sample cohort to 
confirm that the gene signatures defined previously replicate satisfactorily in a similar 
clinical setting. It may be performed by the same research team or ideally by others. 
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These additional steps reduce false positives and the potential for biases [Michiels et 
al., 2007, 2011]. 
f) Establishing a consensus to optimize each step of the procedure would 
therefore generate more reproducibility in results from different studies. Evidence-
based guidelines to perform meta-analysis of array data are in progress [Ramasamy et 
al., 2008] but establishing consensus in experimental design and protocols is still the 
most likely method to minimize variation. Clinical trials to confirm the gene 
signature’s clinical utility on diagnosis and treatment decisions are mandatory, after 
the identification of reliable biomarkers. 
The data from our research work are presented below. 
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2.3.2. RNA microarray analysis 
Pimentel-Santos FM, Ligeiro D, Matos M, Mourão AF, Costa J, Santos H, Barcelos A, 
Godinho F, Pinto P, Cruz M, Fonseca JE, Guedes-Pinto H, Branco JC, Brown MA, Thomas 
GP. Whole blood transcriptional profiling in ankylosing spondylitis identifies novel 
candidate genes that might contribute to the inflammatory and tissue-destructive disease 
aspects. Arthritis Res Ther. 2011 Apr 7; 13(2): R57. 
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3. DISCUSSION AND CONCLUSIONS 
3.1. LESSONS FROM EPIDEMIOLOGICAL ANALYSIS 
3.1.1. Metrological and epidemiological data relevance 
 
The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) [Garret et al., 1994], the 
Bath Ankylosing Spondylitis Global Score (BASG) [Calin et al., 1994], the Bath Ankylosing 
Spondylitis Functional Index (BASFI) [Jones et al., 1996], as well as the Bath Ankylosing 
Spondylitis Metrologic Index (BASMI) [Jenkinson et al., 1994] were developed in the 90’s at 
the Royal National Hospital for Rheumatic Diseases in Bath, UK. These indices are widely 
used by the scientific community and are currently key-elements in assessing and monitoring 
activity, functioning, and mobility repercussions of AS. In addition, several components of 
the BASDAI, BASFI, BASG and BASMI are included in the Assessment of 
SpondyloArthritis Society (ASAS) score set for symptom modifying antirheumatic drugs and 
physical therapy [van der Heijde et al., 1999], the ASAS 20, 40, 60, 5/6 improvement criteria 
and partial remission criteria [Anderson et al., 2001]. Several components of the BASDAI are 
also parameters used in the ASDAS [Lukas et al., 2009; van der Heijde et al., 2009; Machado 
et al., 2011].  
Worldwide distribution of AS and the importance of these indices set the need for a 
homogenous assessment. Therefore, these indices have been cross-culturally adapted for use 
in numerous languages. Despite their importance, these indices haven’t validated in 
Portuguese language yet. For this reason, the original English versions were translated, 
culturally adapted, and validated. The Portuguese adapted versions of these indices 
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maintained all the properties of the original English versions of the instruments. Disease 
activity, functioning, and severity in Portuguese-speaking patients with AS may be now 
appropriately evaluated with these versions of the original instruments (Anexe II) [Pimentel-
Santos et al., 2012b]. Not only Portuguese patients can be more correctly and accurately 
assessed, but also more precise comparisons between patients of different ethnicities can be 
carried out. The above-mentioned instruments can, therefore, now be applied in clinical 
practice and for research purposes with great benefit for both Portuguese and international 
scientific communities.  
The reference centile charts developed for Portuguese population for BASDAI, BASFI, 
BASMI and mSASSS represent, in this context, a useful contribution for ethnic comparisons 
[Pimentel-Santos et al., 2012c]. Unfortunately, at this point only the English reference centile 
[Taylor et al., 1998] charts are available to carry out such comparisons. However, the charts 
do provide some descriptive information regarding disease activity, functional impairment, 
metrology and radiological impact in AS, in the same population, over time. Furthermore, 
these reference charts, with visual representation may improve patients’ understanding of the 
disease, which may improve their compliance to treatment. After proper validation (ongoing 
project), they may be applied in clinical practice on an individual basis in order to follow any 
given patient over time. The possibility of adding this method to others, such as ASAS or 
ASDAS, in disease monitoring may be useful for patients as well as for clinicians. Presently, 
reference centile charts performed in Portuguese population seem to confirm the interpretation 
that arose from the English population - women appear to be more functionally impaired than 
men and have higher disease activity, regardless of better metrology (and, in our cohort, less 
radiological change) [Taylor et al., 1998; Pimentel-Santos et al., 2012c]. Overall, these results 
DISCUSSION AND CONCLUSIONS 
  
 
128 
 
show differences between men and women in the phenotypic expression of AS. This topic 
will be discussed in more detail below. 
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3.1.2. Epidemiological comparison between populations and the influence of gender 
There are limited epidemiological data on AS in Portugal despite its prevalence. It is 
important to have a picture of the disease to identify major concerns and to create appropriate 
intervention strategies. Moreover it allows the comparison of data from our population with 
other ethnic groups and a better characterization of the disease when different subgroups are 
considered. 
In the present work, a comparison of clinical features, activity, functional, metrological, and 
radiographic scores was also carried out between males and females. In fact, the aim of this 
research was not only to characterize AS in Portugal, but also to make comparisons with other 
ethnic groups (Table 2) and to understand the potential influence of gender on phenotypic 
characteristics of the disease and its prognosis (Table 3).  
AS usually begins in late adolescence or early adulthood; onset after 40 years is very rare 
[Zink et al., 2000; Reveille, 2008]. In agreement with this, the mean age of disease onset in 
Portugal is 26.5 years, with juvenile onset (under 16 years) in 10.6% of patients and late onset 
(older than 40 years) in 10% of them. Regarding the gender, mean age of disease onset in 
males is slightly lower (25.8 years) than in females (27.5 years), a difference that is not 
nevertheless statistically significant. These results are similar to those reported in other 
countries [Geirsson et al., 2010]; although there are some variability that in some cases 
reaches statistically significant difference [Aggarwal & Malaviya, 2009; Kim & Kim, 2010]. 
However, there are descriptions that the average age at disease onset is slightly earlier in 
females than in males [Feldtkeller et al., 2003; Lee et al., 2007]. 
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Table 2: Clinical comparison of different ethnic groups with AS published after 2000. 
 Portugal Spain Brazil Argentina India Korea Greece 
Author 
Pimentel-Santos et al., 
2012c 
Garcia  et al., 2008 Sampaio- Barros, 2011 Buschiazzo  et al., 2011 Aggarval & Malaviya, 
2009 
Kim & Kim, 2010 Alamanos  et al., 2004 
n 369 1422 736 86 70 830 113 
Male:Female, n(%) 232/137(62.8/37.1) 1069/353(75.2/24.8) 570/166(77/23) 76/10(88.4/11.6) 59/11(84.3/16.7) 732/98(88.2/11.8) 93/20 
Age, mean(SD) 45.4(13.2) 48.4(12.7) - 40 23.6(8.8) 33.2(10.1) - 
Age symptom onset, mean(SD) 26.5(10.8) 26.9(10.4) 27.7(11.4) - 23.6(8.8) 20.9(8.1) 30.5(10.7) 
Diagnosis delay, mean(SD) 7.6(9) 13.5(10.5) - 3* 6.9(5.2) - - 
Family history 17.6% 20.2% 16.9% 20.9% 52.9% 19.6% - 
Extra-articular manifestations 35.2 - - - 29.6 - 13.3 
AAU 33.6% - - - 25.7% 29.7% - 
BASDAI, mean(SD) 4.2(2.3) 4.1(2.3) 4.6(3.3) 3.9* 3.2(1.8) - - 
BASFI, mean(SD) 4.1(2.7) 3.9(2.7) 4.9(2.7) 4* 2.3(2.0) - - 
BASMI, mean(SD) 4.0(2.5) - - - 3.15(2.3) - - 
HLA-B27 80.5% - - - 92.9% 94.8% 80.5% 
*median; AAU acute anterior uveitis 
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Table 3: Clinical comparison between females and males in different ethnic groups published after 2000. 
 
 Portugal USA India Korea Brazil Iceland 
Author 
Pimentel-Santos et al., 
2012c 
Lee et al., 2007 Aggarval & Malaviya, 2009 Kim & Kim, 2010 Sampaio- Barros, 2001 Geirsson et al., 2010 
Gender Male Female Male Female Male Female Male Female Male Female Male Female 
n 232 137 302 100 59 11 732 98 124 23 145 78 
Age, mean(SD) 45.7 (13.5) 44.9(13.9) 55.5(10.6) 53.0(11) - - 32.9(9.9) 35.4(9.9) - - - - 
Age symptom onset, mean(SD) 25.8(10.8) 27.5(10.8) 23.6 (7.9)* 21.5(7.3)* 22.3(8.5)* 30.0 (8)* 20.6(8)* 23.3(8.9)* - - 23.6(8.4) 24.1(8.9) 
Diagnosis delay, mean(SD) 7.1(9) 8.3(9) - - 6.5(4.7) 8.6(6.6) - - - - 8.3(7.7) 9.6(10) 
Family history 15.2% 21.9% 24.6% 41% - - 18.3% 29.3% 15.3% 8.7% - - 
AAU 34.7% 33.9% 42% 44% 16.9% 72.7% 28.2% 40.8% 15.3% 8.7% 37.9% 30.8% 
BASDAI, mean(SD) 3.7(2.2) 4.9(2.3) - - - - - - - - - - 
BASFI, mean(SD) 3.8(2.6) 4.5(2.7) 4.1 4.2 - - 1.8(1.9) 1.8(2)- - - - - 
HLA-B27 83.2% 76.4% 88.7% 84% - - 94.9% 93.7% 78.2% 78.2% 85.5% 80.8% 
*median; AAU acute anterior uveitis 
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Until now, no sound explanations were proposed for these divergent results in AS. One may 
speculate that different methodologies between studies may account for such differences in 
results; likewise, the importance given to symptoms as a function of gender may also not be 
negligible. The age at diagnosis in Portugal (34.1 years) seems to be significantly lower in 
males than in females (33 years vs 35.8 years, p<0.05, respectively), which is due both to 
lower ages of symptom onset, as previously discussed, and a lower diagnosis delay (7.1 years 
vs. 8.3 years, p>0.05, respectively) in males. The delay identified in the overall Portuguese 
cohort (7.6 years) and between genders is similar to that reported recently in other countries 
[Reed et al., 2008; Aggarwal & Malaviya, 2009; Geirsson et al., 2010]. Based on these and 
other earlier studies [Calin et al., 1988], female patients have shown to have a longer delay 
(1-2 years) before their diagnosis is established although in the majority of these studies no 
statistical differences between genders were reported; likewise, Portuguese population yielded 
similar findings. This tendency might be related with misconception among health care 
providers that AS is a disease of men leading to a widespread insensitivity to recognize AS in 
women. 
 Interestingly enough, the present work showed a lower male:female ratio of 1.7:1. Similars 
values (1.9:1) were reported in Iceland [Geirsson et al., 2010] and in Switezerland [Brunner et 
al., 2002]. Slightly high values of 3-4:1 was reported in USA [Lee et al., 2007], Brazil 
[Sampaio-Barros et al., 2011], Spain [Garcia et al., 2008] which is quite different from 
reports of 8-10:1 in some Asian populations [Kim & Kim, 2010; Zeng, 2003] or in earlier 
studies [Sigler et al., 1971; Wright & Moll, 1973]. One may hypothesize that different 
methodologies (inclusion/exclusion criteria, community vs hospital based studies) may 
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explain these differences; regional variability in terms of genetic background and in terms of 
environment may also have some influence.  
A general tendency for decrease of male:female ratios over time, may be related to better 
knowledge that both patients and scientific community have about AS and also to a better 
access to diagnostic tools. On the other hand, possible gender differences in disease patterns 
may confer additional diagnosis difficulties. The perception that diagnosis of AS is not as 
easily reached in women as it is in men - and that disease may therefore be underdiagnosed in 
women - was the reason to carry out an extensive evaluation of symptoms, disease activity, 
functioning, and metrologic repercussion of AS patients in this study. 
The Portuguese data seems to report a traditional AS patient group having lower back pain 
(42.3%) as an onset symptom. At the time of assessment 49.9% had axial disease, 2.4% 
peripheral disease, 40.9% mixed disease and 7.1% isolated enthesopatic disease. Peripheral 
joint involvement is usually described as an onset symptom in 10–20% (11.1% in Portugal, 
non-published data) of patients, and 30-40% of all patients have this symptom at some point 
of their disease course [Ginsburg & Cohen, 1983; Gran, 1985a; Eastmond, 1996]. Hips and 
shoulders are the most frequently implicated extra-spinal joints in AS; they are concerned at 
onset in up to 15% of patients and at some stage of disease in up to 35% [van der Linden & 
van der Heijde, 2000]. According to a systematic review of earlier studies women had less 
severe involvement of the spine and more peripheral arthritis [Levitin & Davis, 1975; Resnick 
et al., 1976; Braunstein et al., 1982; Marks et al., 1983; Will et al., 1990; Eustace et al., 1993; 
Jimenez-Balderas & Mintz, 1993] than males. When rachis is affected in women the 
involvement tends to be more pronounced in cervical segment [Tyson et al., 1953; Resnick et 
al., 1976; Marks et al., 1983; Maldonado-Coco et al., 1985]. However, a number of 
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methodological issues limits the conclusions that can drawn from these studies. Interestingly 
in Portugal, the proportion of females (53.3%) with peripheral involvement seems to be 
higher than in males (41.7%) in accordance with other recent studies [Lee et al., 2007; 
Geirsson et al., 2010]. All together these results reinforce earlier studies conclusions despite 
conflicting results from India [Aggarwal & Malaviya, 2009] and Korea [Jung et al., 2010], 
where no differences in peripheral joint involvement between genders were found. Other 
differences between male and female might be evident in extra-articular manifestations which 
were experienced by 35.2% of the Portuguese patients, being AAU (33.6%), the most 
common feature [Pimentel-Santos et al., 2012c]. This is in agreement with the literature 
reporting AAU as the most common extra-articular manifestation in AS occurring in up to 
40% patients [Reveille, 2008]. Most studies [Gran et al., 1985b; Rosenbaum, 1989; Rothova 
et al., 1992; Jimenez-Balderas & Mintz, 1993; Tay-Kearney et al., 1996; Lee et al., 2007; 
Geirsson et al., 2010] didn’t show any significant differences in AAU between genders, as it 
was the case of Portugal (35% male vs. 33.3% female, p>0.05). Some conflicting results are 
reported in studies performed in Asian population showing that AAU in females was 
significantly more common [Aggarwal & Malaviya, 2009; Kim & Kim, 2010]. It’s possible 
that ethnicity may play a role in such differences but methodological differences might not be 
excluded.  
Overall, there aren’t in the literature convincing explanations regarding different phenotypic 
characteristics between genders. If current data on sex steroid hormones provide no 
straightforward explanation for the male predominance in AS [Straub et al., 2002] no 
information is available regarding its influence in clinical manifestations. Their role is still not 
completely understood [Masi, 1992; Giltay et al., 1999; Straub et al., 2002]. Alternative 
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explanations for these differences may be found in sexual chromosomes.  However, no 
linkage was found between the X chromosome and susceptibility to AS [Hoyle et al., 2000; 
Zhang et al., 2004]. No evidence comes from recent GWAS performed where no association 
has been established between sexual chromosomes and AS susceptibility [Burton et al., 2007; 
Evans et al., 2011]. No data are available regarding disease phenotype. Further studies are 
required to clarify hormones and sexual chromosomes in disease pathogenesis.  
In this context AS / SpA family history or HLA-B27 positivity becomes particulary interesting 
as it might help in the analogy process, thus contributing to a decrease in the diagnosis delay. 
In this topic there are once again, discrepant results in published studies. It seems to be a 
tendency for women to report family history of AS in first-degree relatives more often than 
males. In some studies the difference reaches statistical difference [Lee et al., 2007; Kim & 
Kim, 2010], but not in others [Aggarwal & Malaviya, 2009]. In Portugal, family history was 
reported in 17.6% of patients in the overall cohort; although females reports family history 
more often than males (15.2% males vs. 21.9% females, p>0.05), the difference is not 
statistically significant. Thus the finding that more females have positive family histories 
could suggest that the diagnosis of AS may be made more often in females when suspiction 
for AS is heightened. This may partially explain lower male:female ratios in such populations, 
but it doesn’t seems to be a reasonable explanation for Koreans [Kim & Kim, 2010]. In 
addition similar proportions of HLA-B27 positivity were described in both genders [Hill et al., 
1976]. HLA-B27 is positive in 80.3% of AS Portuguese patients, a value similar to the one 
found in Greece (80.5%) [Alamanos et al., 2004] but lower than the one referring to India 
(92.9%) [Aggarwal & Malaviya, 2009] or to Korea (94.8%) [Kim & Kim, 2010]. In Portugal, 
proportion in males and females was 82.4% vs. 75.4% (p>0.05), respectively. Similar results 
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were described in USA (88.7% vs. 84.0%, p>0.05) [Lee et al., 2007], in Korea (94.9% vs. 
93.7%, p>0.05) [Kim & Kim, 2010], in Iceland (85.5 vs. 80.8 %, p>0.05) [Geirsson et al., 
2010] and in Brazil (78.2% vs. 78.2%, p>0.05) [Sampaio-Barros et al., 2001]. Although it is 
not possible from these studies to estimate the real impact of HLA-B27 positivity on 
diagnosis delay, a study [Feldtkeller et al., 2003] showed that the delay is significantly longer 
in HLA-B27 negative than in HLA-B27 positive patients. 
In terms of activity and severity of disease, data gathered in this study showed high mean 
values of  BASDAI (4.2), BASFI (4.1), and BASMI (4.0). Although these values are similar 
to those found in other populations, it also means Portuguese patients have, on average, high 
levels of activity and disease severity. In other words, this means that the disease is not 
adequately controlled in a large number of patients. Considering gender, as previously 
discussed, it has been increasingly recognized that AS is not so uncommon in females. 
Furthermore, the symptoms they experience are at least of similar severity [Zink et al., 2000], 
or even worse, than in males [Pimentel-Santos et al., 2012c]. In fact, as previously reported in 
English and presently in Portuguese patients, females have more self-reported disease activity 
and more functional impairment than males, despite their better metrology [Taylor et al., 
1998] and a better radiological evaluation (mSASSS) [Pimentel-Santos et al., 2012c]. These 
differences were valid for results as a whole, but also when different periods of disease 
duration were considered [Pimentel-Santos et al., 2012c]. Less structural changes in women 
than in men has been highlighted previously [Feldtkeller & Braun, 2000; Lee et al., 2007] but 
for a given degree of radiographic damage, women reported more functional limitations [Lee 
et al., 2007]. However, the relationship between accumulation of spinal radiographic damage 
and corresponding function in AS remains unknown.  
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Overall, these data highlight the idea that there are different phenotypic patterns in AS 
according to the gender. In addition the relatively slow clinical and radiological development 
in women [Jimenez-Balderas & Mintz, 1993], potentially contribute to a more difficult 
recognition, which in turn leads to misdiagnosis in early stages of the disease. It is important 
to considerer the overall diagnosis delay of eight years, which appears to be very long. 
Several potential explanations have been identified:  
- One of them is lack of sensitivity of the modified New York Criteria when used in clinical 
practice. Therefore it would be interesting to evaluate in a few years the changes introduced 
by new ASAS criteria for axial and peripheral spondylarthritis [Rudwaleit et al., 2009b, 
2009c; Rudwaleit, 2010a, 2010b]; 
- Another reason may be the non-recognition of inflammatory back pain by patients and/or 
caring physicians and/or difficulty in accessing rheumatology care. In order to solve the 
problem of lack of information, the Portuguese Society of Rheumatology has recently 
promoted several campaigns in different media. In order to improve the coverage of 
Rheumatology care, the General Directorate of Health (DGS) has likewise implemented a 
network of rheumatology referral hospitals according to a National Program Against 
Rheumatism (“Programa Nacional Contra as Doenças Reumáticas”). As a consequence, 
several rheumatology units have been established in different regions of Portugal. It will be 
interesting to evaluate in the next few years the impact of all these health care strategies in 
terms of disease activity, severity and HRQoL parameters. 
Discussion of results has been articulated around diagnosis delay in order to bring out 
strategies for an earlier diagnosis and, therefore, avoid delayed therapy onset, which in turn 
might be an additional detrimental factor for prognosis [O'Dell, 2002]. A growing body of 
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evidence emphasizes that prognosis improves when patients with early RA or undifferentiated 
arthritis are referred to, and managed by, experts in aggressive rheumatologic care [Cush, 
2007]. Additionaly, there is a period in early RA onset (“window of opportunity” concept 
[O'Dell, 2002]) during which there is great potential for remission and/or for obtaining a 
better clinical response. Although the scientific community extrapolated these ideas to SpA; 
clinical evidence still lacks in this area. Interestingly, in the analysis performed in Portuguese 
population, no statistical difference was found between patients with early and late diagnosis 
in terms of disease activity, function, metrology and radiological repercussion, which suggests 
that early diagnosis (and subsequent early therapy onset) may not indicate better prognosis. 
However, these results must be interpreted in the light of the cross-sectional, observational 
study design. As commented in the paper, one possible explanation may be that early 
diagnosis is associated with a more active disease, which decreases the potential benefit of an 
early intervention rather than simply reflecting paucity of benefit of an early treatment. On the 
other hand, many patients in this cohort were diagnosed as AS cases more than 10 years ago, 
when therapeutic strategies were clearly different from those currently available. The 
relevance of the delay in diagnosis should prompt a detailed evaluation in future studies. 
In this context it would be interesting analyse therapeutic approach of the Rheumatology 
community. From the BASDAI charts analysis it is interesting to confirm previous findings 
that AS remains active over the disease course [Kennedy et al., 1993], in both genders 
[Pimentel-Santos et al., 2012c]. This observation has clinical implications, and influence 
therapeutic decisions even on longstanding AS cases. No analysis in this subject was 
performed in this cross-sectional study. However, comprehensive assessment of different 
therapeutic approaches can be made. Globally, there is widespread use of nonsteroidal anti-
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inflammatory drugs (NSAIDs) as seen in Portugal (79.1%). Unfortunately, due to the nature 
on data collection it was not possible to analyze the influence of “daily” vs. “on demand” 
therapy in disease severity. There is some evidence in the literature suggesting that chronic 
systematic daily intake may have a beneficial effect at structural level [Wanders et al., 2005a]. 
Additional studies are needed in this field. Interestingly corticosteroids prescription is high 
(17.6% in total; 12.5% in axial form). Similar results were reported in a previous publication 
involving SpA (predominantly AS) Portuguese patients [Sousa et al., 2008]. The proportion 
of prednisone prescription were higher in females (16.6% males vs. 20.3% females, p>0.05) 
than in males as it happens in PSOAS cohort (3.6% males vs.10% females, p<0.05) - another 
cross-sectional study, performed in North America, involving patients over 20 years of 
disease duration, [Lee et al., 2007]. The prescription of Sulphasalazine (SSZ) is also high 
(overall prescription of 36.9%, in monotherapy 30.9%) even when considering axial disease 
presentation exclusively (32.1%). There weren’t any significant differences between genders 
(37% in males vs. 36% in females, p>0.05), as in the PSOAS cohort (6.6% in males vs 11% in 
females, p>0.05) [Lee et al., 2007], despite of remarkable high proportion of patients taking 
SSZ in Portugal. This seems to be related with the emerging data supporting SSZ use in early 
inflammatory back pain and not only in peripheral arthritis involvement [Goh & Samanta, 
2009]. The high corticoids and SSZ prescription (even in axial forms of the disease) are 
probably related to the perception by the Portuguese Rheumatologists of high disease activity. 
Contrarily, and paradoxically, anti-TNFα prescription was generally low (22%). In fact, the 
need for anti-TNFα therapy was previously estimated as 30-49% [Barkham et al., 2005; Pham 
et al., 2006]. The high frequency of co-morbidities, functional impairment, and active disease 
despite the optimal use of NSAID therapy were the main reasons appointed to start anti-TNFα 
therapy in Belgium [Vander Cruyssen et al., 2007]. The study performed in Portugal didn’t 
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allow patients characterization when anti-TNFα therapy was started. However, there is 
indirect evidence - positive correlation between BASMI and anti-TNFα therapy,that 
biological treatments began late in the course of the disease. The low anti-TNFα associated 
with high corticoids and SSZ prescriptions may indirectly indicate some economic issues, or 
alternatively some concerns about using drugs recently introduced in the market. This aspect 
could explain, at least partially, the lack of adequate control of the disease. 
Finally, this study aimed to examine the socio-economic impact of AS and the influence of 
gender in this context. A detailed assessment of this topic has not been undertaking so far. 
The available data in the literature is scarce and are limited to studies conducted in the USA 
[Singh & Strand, 2009] and Taiwan [Chen et al., 2011]. Both studies were based on 
administrative database, but report different conclusions. The USA study reports that gender 
didn’t influence healthcare utilization in AS patients. The Taiwanese study reports that men 
had increased risk of high cumulative outpatient visits and a trend for high frequency of 
hospitalization. Methodological aspects may explain again these differences. The USA study 
investigated both AS and non-AS related healthcare utilization for only one year and has just 
examined the gender factor as it was based in a veteran population. The Taiwanese only 
focused in AS related healthcare utilization over 12 years. According to data collection it is 
possible to anticipate the limitations of the study performed in Portuguese population. It was 
hospital-based (tertiary rheumatology practices), so despite being a representative population, 
it may have different socio-demographic characteristics in comparison to community-based 
studies. Another restricting factor concerns data collection - “patient-reported”. It is well 
known the inaccuracy of patient-reports, with under-reporting juxtaposed to a higher number 
of visits, compared with medical record ascertainment [Roberts et al., 1996]. Nevertheless, in 
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terms of society and health politics it is relevant to analyze the Portuguese data in order to 
show the differences in health care systems and country settings, which underlie the obtained 
disparity in different countries. Furthermore this study may contribute to identify the 
predictors for higher cumulative healthcare services utilization in both genders.  
In summary, this data analysis point out ethnic differences and suggest that the AS phenotypic 
pattern might be different according to the gender. The underlying pathogenesis of these 
differences is still unknown, warranting further investigation of the topic. In this field, genetic 
studies represent an important tool to clarify the mechanisms involved in AS.  
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3.2. LESSONS FROM DNA TECHNOLOGIES IN ANKYLOSING SPONDYLITIS 
 
There is a great need for further research on disease etiopathogenesis and for development of 
new therapies in AS. Recent advances in the genetics of AS provide a huge amount of 
information that needs validation. The present work aimed at contributing to this field.  
3.2.1. GWAS and Ankylosing Spondylitis 
 
The first-large scale SNP association study in AS, was the WTCCC/TASC study; it involved 
the genotyping of 14,436 non-synonymous SNPs (nsSNP) and 897 major histocompatibility 
complex (MHC) SNPs, in 1000 cases and 1500 controls [WTCCC/TASC, 2007]. As this 
study only addressed the genes’ coding regions, a large proportion of the overall genetic 
diversity remained uncovered [WTCCC/TASC, 2007]. Two major genes, Interleukin 23 
Receptor (IL23R) and Endoplasmic Reticulum Aminopeptidase 1 (ERAP1), were identified 
and held responsible, for 9% and 26%, respectively, of the population attributable risk of AS. 
These findings changed the focus of immunological research in AS to TH17 lymphocytes, as 
these cells express IL23R and hypothesized the interaction between ERAP1 and HLA-B27 in 
peptide presentation. However, most associations may involve non-coding sequences.  
The TASC study conducted in 2,053 unrelated AS cases among people of European descent 
and 5,140 ethnically matched controls, with replication in an independent cohort of 898 AS 
cases and 1,518 controls [TASC, 2010], has led to interesting results. In addition to the strong 
association with the major histocompatibility complex, association with SNPs in two gene 
deserts at 2p15 and 21q22, as well as in Anthrax Toxin Receptor 2 (ANTXR2) and Interleukin 
1 Receptor, Type II (IL1R2) genes were identified. The previously reported associations of 
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IL23R and ERAP1 to disease were also replicated [TASC, 2010]. Furthermore, Caspase 
recruitment domain family, member 9 (CARD9), and Tumor necrosis factor receptor 
superfamily, member 1A - Associated via Death Domain (TRADD genes provide suggestive 
evidence of association with AS in two follow-up studies [Pointon et al., 2010a, 2010b]. 
In the recently published TASC/WTCCC2 study, Runt-related transcription factor 3 
(RUNX3), Tumor necrosis factor receptor superfamily, member 1A (TNFRSF1A), Interleukin 
12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40) 
(IL12B), Prostaglandin E Receptor 4 (subtype EP4) (PTGER4), TBK1 binding protein 1 
(TBKBP1), and again ANTXR2 and CARD9 regions showed definite association with AS 
[Evans et al., 2011]. A summary of all involved genes is presented in Table 4 and Figure 2 
(where a spatial genes’ distribution in chromosomes is presented).  
Recent findings suggest that Tumor Necrosis Factor (ligand) Superfamily, Member 15, 
(TNFSF15) [Zinovieva, 2009] and/or Tumor Necrosis Factor (ligand) Superfamily, Member 8 
(TNFSF8) [Zinovieva, 2011] may be involved in AS. Neither of these genes was associated 
with disease in the previous TASC/WTCCC studies [WTCCC/TASC, 2007; TASC, 2010, 
Evans et al., 2011]. As mentioned earlier, a detailed analysis of the genes studied in the 
Portuguese population will be discussed. 
 
 
 
 
 
 
DISCUSSION AND CONCLUSIONS 
  
 
144 
 
Table 4: Summary of genetic associations with AS.  
 
Gene Locus Studies Definite/Suggestive 
Contribution to AS 
(%) 
Mechanism 
HLA-B27 6q21 
Brewerton,1973 
Schlosstein,1973 
Definite 23.3 Presentation peptides to T-cells 
Gene deserts 2p15 TASC,2010 Definite 0.543 Unknown 
ERAP1 5q15 WTCCC/TASC,2007 Definite 0.34 
Peptide trimming to HLA class I  
presentation 
IL23R 1p31 WTCCC/TASC,2007 Definite 0.31 Differentiation of IL23R expressing cells 
KIF21B 1q32 Danoy P,2010 Definite 0.25 Unknown 
RUNX3 1p36 Evans DM,2011 Definite 0.12 Reduction in CD8 lymphocyte counts 
IL1R2 2q11 TASC,2010 Definite 0.12 Influence on IL-1 response 
IL12B 5q32 Danoy P,2010 Definite 0.11 Differentiation of IL23R expressing cells 
TNFR1 12p13 
TASC,2010 
Davidson,2010 
Definite 0.075 TNF signaling 
ANTXR2 4q21 Evans DM,2011 Definite 0.054 Unknown 
TBKBP1 17q32 Evans DM ,2011 Definite 0.054 TNF signaling 
PTGER4 5p13 Evans DM ,2011 Definite 0.052 
Induction of IL23 expression/Differentiation 
of IL23R expressing cells/ Bone anabolism. 
Gene deserts 21q22 TASC,2010 Definite 0.035 Unknown 
CARD9 9q34 
TASC, 2010 
Pointon, 2010 
Definite 0.034 Th17 activation after β-glucan exposure 
TNFSF15 9q32 Zinovieva, 2009 Suggestive - Th17 activation/differentiation 
TRADD 16q22 Evans DM ,2011 Suggestive - TNF signaling 
STAT3 17q21 
Danoy P,2010 
Davidson,2010 
Suggestive - Differentiation of IL23R expressing cells 
KIR3DS1 19q13 Zvyagin, 2010 Suggestive - NK cell inhibition/activation 
TNFSF8 9q33 Zinovieva, 2011 Suggestive - CD30L/CD30 signaling 
Level of confidence – ‘Confirmed’ indicates P<5x10-7 in one study, with replication in a second cohort. ‘Suggestive’ indicates 10-5<P<5x10-7 in one study, or P<5x10-7 
but no replication. (Adapted from Brown, 2011). 
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Figure 2 - Chromosomal locations of genes implicated in AS susceptibility in GWAS. (Adapted from Santos et al., 2007) 
 
 
3.2.2. MHC genes  
3.2.2.1. HLA-B27 
 
The MHC on chromosome 6p is the main locus strongly linked and associated with AS, 
although, as determined forty years ago, the majority of genetic associations are driven by 
HLA-B27 allele [Schlosstein et al., 1973; Brewerton et al., 1973]. HLA-B27 is present in more 
than 80% of white European AS cases, compared with approximately 8% of healthy controls 
[Brown et al., 1996]. Our study has shown that 80.3% of AS Portuguese patients are HLA-
B27 positive [Pimentel-Santos et al., non-published data]. The worldwide distribution of 
HLA-B27 varies considerably, as previously commented, and there is a clear decreasing 
gradient in its frequency from north to south [Khan, 1995; Gonzalez-Roces et al., 1997; 
Blanco-Gelaz, 2001]. In general, the prevalence of AS is strongly correlated with HLA-B27 
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distribution and the strength of their association varies among different ethnic populations 
[Blanco-Gelaz, 2001]. However, in the general population only 1-5% of HLA-B27 positive 
subjects develop AS [van der Linden et al., 1984b; Gran et al., 1985a; Braun et al., 1998]; the 
proportion increases to 20% in positive relatives of AS patients [van der Linden et al., 1984b]. 
Family or twin studies have estimated a range from 16 to 50% for HLA-B27 contribution to 
AS [Rubin, 1994; Brown et al., 1997; Brown et al., 1998a] while the whole effect of the 
MHC is approximately 50% [Brown et al., 1998; Laval et al., 2001; Zhang G et al., 2004]. 
Independent twin studies have shown that heritability of susceptibility to AS is over 90% 
[Brown et al., 1997; Pedersen, 2006], and it is likely that other genetic factors (inside and 
outside the MHC) may influence susceptibility to AS.  
Despite extensive research over the past decades, the exact mechanism underlying the effect 
of HLA-B27 on AS susceptibility has not yet been established. Several theories have tried to 
explain possible underlying mechanisms and include: 
a) Canonical mechanisms: 
- The “arthritogenic peptide” theory explains the association of HLA-B27 with AS in 
terms of the function of HLA-Class I molecules in peptide presentation to CD8+ T 
lymphocytes [Kuon et al., 2001; Boyle & Gaston, 2003; Sims et al., 2004]. 
- The “molecular mimicry” theory focused in cross-reactivity between host self' 
antigens and specific disease triggering microorganisms’, presented by HLA-B27 or 
HLA-class II presentation to CD4+ T lymphocytes [Schwimmbeck & Oldstone, 1988; 
Benjamin & Parham, 1992; Boyle et al., 2001; 2004a; 2004b; Boyle & Gaston, 2003]. 
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b) Non-canonical mechanisms: 
- The induction of endoplasmic reticulum stress due to the propensity of HLA-B27 to 
fold slowly and inefficiently [Mear et al., 1999; Martin, 2002]. 
- The occurrence of abnormal forms of HLA-B27 such as homodimers, leading to 
aberrant immunological reactions [Allen et al., 1999]. 
- The release of β2-microglobulin from a subpopulation of cell surface - expressed 
HLA-B27 molecules leads to its deposition within synovia and to the initiation of an 
inflammatory process [Uchanska-Ziegler & Ziegler, 2003]. 
- The nearby “linked gene” theory, that proposes HLA-B27 as a marker for a nearby 
true disease susceptibility locus [Nijenhuis, 1977]. 
Until now (July 2011), eighty-one (HLA-B*2701-B*2782; B*2722 has been removed because 
it resulted from a sequencing error) molecular HLA-B27 subtypes have been assigned, and 
many other synonymous polymorphisms were reported in B27 alleles (in The Antony Nolan 
Trust database, http://hla.alleles.org/alleles/class1.html). Most subtypes have only been 
reported in a few individuals and, therefore, it is not possible to know whether they are 
associated with AS [Reveille & Maganti, 2009]. However, there are reports of AS or SpA 
association with HLA-B*2701 [MacLean et al., 1993], B*2702 [MacLean et al., 1993], 
B*2703 [Armas et al., 1999], B*2704 [López-Larrea et al., 1995a], B*2705 [MacLean et al., 
1993], B*2706 [Gonzalez-Roces et al., 1997], B*2707 [Armas et al., 1999], B*2708 [Armas 
et al., 1999], B*2710 [García et al., 1998], B*2714 [García-Fernández et al., 2001], B*2715 
[García-Fernández et al., 2001] and B*2719 [Tamouza et al., 2001]. Actually, there is 
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evidence that distinct subtypes are differentially associated with AS; two subtypes, B*2706 
and B*2709, found in southeast Asia and Sardinia, respectively, have shown significantly 
reduced association with AS [D'Amato et al., 1995; Lopez-Larrea et al., 1995a]. In our 
Portuguese population, only B*2705 and B*2702 were identified in AS patients (n=51); in 
controls (n=16), B*2707 was also identified [Pimentel-Santos et al., 2007]. 
 
3.2.2.2. Other MHC genes 
 
Several MHC genes have been implicated in AS susceptibility and/or its clinical 
manifestations. In fact, about 10% of Caucasian patients with AS are HLA-B27 negative 
[Schlosstein et al., 1973; Brewerton et al., 1973]. In Portugal [Pimentel-Santos et al., 2012c] 
and Greece [Alamanos et al., 2004] the proportion of HLA-B27 negative is about 20% and in 
Turkey is even high (about 30%) [Gunal et al., 2008]. The association of HLA-B60 (B*40) in 
both, HLA-B27 positive and negative individuals, has been largely replicated and confirmed 
in groups such as Taiwanese, Chinese and Europeans [Robinson et al., 1989; Rubin et al., 
1994; Brown et al., 1996; Wei et al., 2004]. Others HLA-B associations have been reported 
such as HLA-B38 and HLA-B39 in Japanese [Yamaguchi et al., 1995], and HLA-B35 and 
HLA-B62 in HLA-B27 negative Caucasians patients [Wagener et al., 1984]. However, these 
associations have not been independently confirmed in additional studies. In our Portuguese 
population only HLA-B8 was significantly increased in AS patients versus controls (p=0.003, 
OR=3.97, 1.47<CI<10.8). However, after Bonferroni correction no statistically significant 
differences were found between both groups.  
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Other MHC class I genes have been tentatively  associated with AS, in particular MICA, but 
the association was better explained by LD with HLA-B27 [Yabuki et al., 1999; Martinez-
Borra et al., 2000; Ricci-Vitiani et al., 2000; Singal et al., 2001;].  
MHC class II alleles have been also implicated in AS susceptibility, such as HLA-DRB1*01, 
(independently of HLA-B27) in the British and Mexican population [Brown et al., 1998b; 
Vargas-Alarcon et al., 2002a], HLA-DRB1*08 in British [Brown et al., 1998b] and HLA-
DQ*02 in Spanish patients [Sanmartí et al., 1987]. In addition, HLA-DRB1*08 seems to 
confer susceptibility to AAU [Monowarul Islam et al., 1995]. Transporter 1, ATP-binding 
cassette, sub-family B (TAP1) and Transporter 2, ATP-binding cassette, sub-family B (TAP2), 
which is located within MHC class II region, was proposed as AS associated but in a Spanish 
study this effect was not seen [Fraile et al., 2000]. The Low molecular weight proteosome 2 
(LMP2) was also implicated in juvenile AS patients from Mexico [Vargas-Alarcón et al., 
2004] and Norway [Ploski et al., 1995] and it also seems to increase risk for AAU in AS 
patients from Canada [Maksymowych et al., 1997]. Moreover, LMP7 alleles have been 
reported to be associated with AS in Spanish patients [Fraile et al., 1998a]. In our population 
no association was established between HLA-DR and HLA-DQ alleles studied and AS. In 
contrast, several associations of these alleles with phenotypic characteristics were identified, 
in HLA-B27 positives patients. DRB1*08 allele seems to be linked to increased risk of AAU, 
whereas DQB1*04 appears to provide consistent protection in terms of disease activity 
(BASDAI), functional (BASFI), metrological (BASMI), and radiological severity (mSASSS). 
Several studies have addressed the association of the MHC class III region and AS. Tumor 
necrosis factor alpha (TNF-α), a macrophage derived cytokine, has been implicated in the 
pathogenesis and development of AS [Tracey & Cerami, 1993]. In addition, TNF-α blockers 
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have proven to be effective in improving AS manifestations, which suggests that TNF is at 
least as important for inflammatory process in AS as it is in other rheumatic diseases [Davis et 
al., 2003; van der Heijde et al., 2005, 2006]. TNF gene has 12 kb and is located in MHC class 
III region, between class I and II regions and adjacent to HLA-B locus [Glossop et al., 2003]. 
Several SNPs are common in TNF gene promoter [Allen, 1999]. These genetic variants could 
affect the binding of transcription factors, which might in turn influence the promoter’s 
activity and, ultimately, mRNA and protein levels [Bayley et al., 2004]. A number of studies 
have been focused on the promoter position −308 (G/A) and −238 (G/A) of the TNF gene 
[Verjans et al., 1994; Fraile et al., 1998b; Hohler et al., 1998; Kaijzel et al., 1999; McGarry et 
al., 1999; Martinez- Borra et al., 2000; Milicic et al., 2000; Gonzalez et al., 2001; Vargas-
Alarcon et al., 2006; Shiau et al., 2007; Lu et al., 2008; Chatzikyriakidou et al., 2009; 
Nicknam et al., 2009; Sousa et al., 2009]. However, there were inconsistent results among 
these studies that might be due to sample size, insufficient statistical power, clinical 
heterogeneity, and ethnic differences.  
In Portuguese population, the low frequency of A allele at -238 position in AS – as compared 
to control and independently of HLA-B27 - suggested a protective role for this allele [Sousa et 
al., 2009]. Similar results were obtained in populations issued from Germany [Hohler et al., 
1998] and Taiwan [Shiau et al., 2007]. On the contrary, in our study no association has been 
detected between polymorphisms at position -308 and AS. Repercussion of these SNPs on 
disease prognosis has been less studied; nevertheless, in national patients, -308 GA/AA and -
238 GA/AA genotypes were associated with a later disease onset and high erythrocyte 
sedimentation rate (ESR) values, respectively [Sousa et al., 2009]. Taken together, these 
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results suggest that TNF gene promoter SNPs at -238 and -308 positions might have a small 
influence on AS susceptibility and disease prognosis. 
Recently, two meta-analysis were performed to evaluate the association of TNF promoter 
polymorphisms with AS susceptibility [Lee & Song, 2009; Li et al., 2010]. No association 
was found between TNF promoter -238 and -308 polymorphisms and AS susceptibility in 
either the overall population or the HLA-B27 positive subjects. Although meta-analysis is a 
powerful method to overcome the problem of small sample size and inadequate statistical 
power frequently encountered in published studies [Egger et al., 1997], some limitations 
existed in both of the above mentioned publications; namely, a small proportion of the AA 
genotype for both positions -238 and -308 in the TNF promoter; differences in gene 
distribution between studies; and publication biases.  Moreover, only two studies investigated 
the role of these polymorphisms in HLA-B27 negative AS patients [Martinez-Borra et al., 
2000; Gonzalez et al., 2001] and in both no definitive conclusions could be taken.  
Heat shock protein (HSP70) is another factor involved in immune response, coded by a gene 
located in MHC class III region, in the vicinity of HLA-B locus. HSP70 gene has been 
investigated regarding its potential influence on susceptibility to AS. There was a significant 
association of HSP70-2 and HSP70-hom alleles with SpA in Mexicans, in both HLA-B27 
positive and HLA-B27 negative individuals [Vargas-Alarcón et al., 2002b]. However, 
conflicting results were obtained in other populations; no association between HSP70 gene 
polymorphism and AS was identified in Chinese Han [Lin et al., 2004, 2007], Finish 
[Westman et al., 1994], nor Spanish [Fraile et al., 1998c] populations. For this reason, this 
gene’s role must still be enlighted in further future studies. There aren’t any available data in 
this regard in Portuguese population. 
DISCUSSION AND CONCLUSIONS 
  
 
152 
 
In summary, despite a broad plethora of published data, results must be interpreted with 
caution as there is still no agreement among different studies. In addition, WTCCC2/TASC 
study [Evans et al., 2011] didn’t find any significant MHC associations except for HLA-B 
locus. 
Extreme allelic diversity in this region and extensive LD makes it difficult to genotype, 
analyze, and identify allele(s) directly associated with pathology. This high diversity adds to 
the possibility that AS might be associated with more than one MHC gene and explains why 
this region is so hard to study [Brown, 2010]. HLA genes are organized in haplotypes which 
renders dissection of individual genes very difficult; it is, thus, also very hard to spot out 
“predisposing” haplotypes. However, it is of utmost importance to identify haplotypes that 
might be linked to disease, either by being causative variants of disease or by influencing the 
disease’s phenotypic characteristics [Fiorillo et al., 2003]. This was the underlying reason to 
have performed extensive haplotypes analysis in this work. 
 
3.2.3. MHC haplotypes  
 
There are several scattered studies in the literature based on MHC-haplotype analysis that 
report conflicting results that hinder clear conclusions. The main reason for differences might 
be related, once again, to under-powered statistical analysis, heterogeneous groups of patients, 
or different methodologies used.  
In our Portuguese population, extended HLA haplotypes in B27 positive patients and controls 
were estimated by Expectation Maximization algorithm using the Arlequin v3.11 software. 
To the author’s knowledge, it was the first study where extended haplotypes were evaluated. 
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A*02/B*27/Cw*02/DRB1*01/DQB1*05 haplotype has been identified exclusively in AS 
patients and it thus seems to confer susceptibility to the disease. In addition, 
A*02/B*27/Cw*01/DRB1*08/DQB1*04 haplotype seems to confer protection in terms of 
disease activity (BASDAI), functional (BASFI), and radiological repercussion (mSASSS). 
[Pimentel-Santos et al., non-published data].  
Previous studies are partial evaluations within MHC. In Sardinia two different haplotypes 
were described as conferring susceptibility to AS, the A*02/B*2705/Cw*02/DR*02 and 
A*02/B*27/Cw*02/DR*16 [Contu et al., 1992; Fiorillo et al., 2003]. In Tunisian [Kchir et al., 
2010] and in British [Sims et al., 2007] populations different haplotypes were also described, 
B*27/DRB1*11/DQB1*03 and B*27/DRB1*07, respectively. Data regarding haplotypes 
involving HLA-B/-Cw are scarce, but B*27/Cw*01 and B*27/Cw*02 were described in 
association with AS in some Caucasian populations [González-Roces et al., 1994; López-
Larrea et al., 1995b; Ben Radhia et al., 2008].  
There is a lack of information in the literature regarding association between MHC-
haplotypes and clinical features of disease. Our Portuguese Study may be a contribution in 
this field. Complementary information was gained from one small cohort study of HLA-B27 
positive Taiwanese AS patients. The haplotypes A*33/B*58/Cw*10, 
A*33/B*58/Cw*10/DR*13, and A*33/B*58/Cw*10/DR*17 showed a strong negative 
association with bamboo spine [Lu et al., 2009].  
This particular field of research remains opens to further understanding and therefore presents 
an excellent opportunity for future studies. 
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3.2.4. Non-MHC genes 
3.2.4.1. ERAP1 
 
The WTCCC/TASC nsSNP study in 2007 led to the identification of ERAP1 as the first non-
MHC gene definitively associated to AS [WTCCC/TASC, 2007]. The association was 
confirmed in Portuguese patients according to our data [Pimentel-Santos et al., 2009] and 
thereafter in a wide variety of ethnic groups, including, Canadians [Maksymowych et al., 
2009], Han Chinese [Davidson et al., 2009; Li et al., 2011], Koreans [Choi et al., 2010], and 
Hungarians [Pazar et al., 2010]. In Portuguese population, the strongest associated ERAP1 
polymorphism was rs27044. However in our data no association was found with marker 
rs2303138 lying in LNPEP, which supports the hypothesis that at least a component of the 
association observed between this SNP and AS, previously reported in British Caucasians, is 
due to LD with ERAP1 polymorphisms [Pimentel-Santos et al., 2009]. Recently, a meta-
analysis was performed to assess the strength of association between ERAP1 polymorphisms 
and AS risk, involving nine case-control studies (total of 8,530 AS patients and 12,449 
controls) [Chen et al., 2011]. This meta-analysis further confirmed that ERAP1 
polymorphisms may play a significant role in AS susceptibility. Except for rs27434, a 
meaningful correlation was detected in rs27044, rs17482078, rs10050860, rs30187, 
rs2287987, and rs27037.  
Considering the imputed and genotyped data across ERAP1 performed in our study, an 
association was seen between SNPs rs26509 and rs190298, an interval of 84 kb. In the 
WTCCC2/TASC, association is clearly localized in a more restrict block of 4.6 kb region 
DISCUSSION AND CONCLUSIONS 
  
 
155 
 
between rs27529 and rs469758. Recently, the primary associated variant(s) in ERAP1, the 
major allele of rs30187, and the minor allele of rs10050860 were shown to confer a protective 
effect against AS [Evans et al., 2011]. This association is restricted to HLA-B27 positive cases 
[Evans et al., 2011].  
No significant association has been reported between ERAP1 and IBD [WTCCC/TASC, 
2007], although there is an association with the enthesitis related arthritis subtype of juvenile 
idiopathic arthritis [Hinks et al., 2011] and psoriasis [Genetic Analysis of Psoriasis 
Consortium & the WTCCC2, 2010; Sun LD et al., 2010]. Interestingly, it appears that ERAP1 
variants only influenced psoriasis susceptibility in individuals carrying the HLA-C risk allele; 
this fact brings to attention the same functional interaction that exists between HLA-Cw6 and 
ERAP1 and between HLA-B27 and ERAP1. In addition, there are moderate levels of 
association with type 1 diabetes [Fung et al., 2009] and cervical cancer [Mehta et al., 2007, 
2008, 2009]. ERAP1 is an aminopeptidase with ubiquitous tissue distribution that is expressed 
in the endoplasmic reticulum. ERAP1 is a zinc-metallopeptidase with typical H-E-X-X-H-
(X)(18)-E zinc binding and G-A-M-E-N motifs characteristic of the members of the gluzincin 
protease family. These structures reveal extensive domain movements, including an active 
site closure, as well as three different open conformations, thus providing insights into the 
catalytic cycle. A K(528)R mutant strongly associated with AS in GWAS studies shows 
significantly altered peptide processing characteristics, which are possibly related to impaired 
interdomain interactions [Kochan et al., 2011]. The exact mechanism by which ERAP1 
influences AS susceptibility is not clear. Two hypotheses have been considered:  
a) To trim peptides, acting as a molecular ruler, down to nine amino acids in length prior 
to loading into nascent HLA class I molecules [Chang et al., 2005; Saveanu et al., 
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2005]. In vitro, the use of recombinant ERAP1 showed that rs31087 and rs17482078 
were associated with markedly reduced peptide trimming, whereas rs10050860 and 
other non-synonymous variants were neutral. However, as previously commented, 
polymorphisms of ERAP1 only affect AS risk in HLA-B27 positive individuals [Evans 
et al., 2011]. These findings are extremely important to determine the mechanism of 
HLA-B27 and AS association.  
 
b) Through its potential role in cleaving pro-inflammatory cytokine receptors from the 
cell wall, including TNFR1 [Cui et al., 2002], IL-1R2 [Cui et al., 2003a] and IL-6R 
[Cui et al., 2003b]. If a definitive association of IL1R2 and a suggestive association of 
TNFR1 with AS were demonstrated, [TASC, 2010], as well as an increase of IL6 
plasmatic levels [Keller et al., 2003], the lack of differences in ERAP1 expression 
between AS and controls, in peripheral blood [TASC, 2010], would show this function 
does not have a significant physiological role. To reinforce this finding, the ability of 
ERAP1 to cleave TNFR1 and IL-6R from cell surfaces was tested by measuring these 
receptors in cell culture supernatants (from single-cell suspensions prepared from 
Erap1−/− and C57BL/6 control mouse spleens). No difference was observed in the 
levels of these receptors over time, indicating that ERAP1 does not have a major 
influence on cytokine receptor cleavage, at least in mice [Evans et al., 2011]. 
 
Further studies in different ethnic groups and new functional studies would bring new insight 
into the mechanisms involved in AS. 
 
 
DISCUSSION AND CONCLUSIONS 
  
 
157 
 
 
3.2.4.2. IL23R 
 
The WTCCC/TASC nsSNP study in 2007 also identified the association of IL23R and AS 
[WTCCC/TASC, 2007]. The association was confirmed in an independent North American 
cohort, and thereafter replicated in a wide variety of ethnic groups, including Spanish [Rueda 
et al., 2008], Canadian [Rahman et al., 2008], Portuguese [Pimentel-Santos et al., 2009] and 
again in English [Karaderi et al., 2009] population. The studies in East Asians did not show 
any association between the gene and AS in Han Chinese [Davidson et al., 2009] nor in 
Koreans [Sung et al., 2009] or in Japanese with Crohn’s disease [Yamazaki et al., 2007], or in 
Chinese with psoriasis [Liu et al., 2008].  
The peak association in our Portuguese cohort was seen with rs1004819, and this finding is 
different from what was found from American, Canadian, Spanish and British data sets, 
although the minor allele frequencies (MAF) observed for SNPs in Portuguese patients were 
similar to those reported in any other populations. Furthermore, the association we observed 
in the Portuguese population had a similar magnitude of effect when compared to the one 
described in those other populations: the attributable risk for rs1004819 is very similar to the 
one reported for the most strongly associated SNP (rs11209032) in the British/North 
American populations [WTCCC/TASC, 2007]. In order to identify the primary SNP variant 
associated to AS, the imputed SNP data showed that a broad region of IL23R is associated 
with AS in Portuguese patients. Association peak range between the SNPs rs10889667 and 
rs11465817, an interval of 66 kb, with a rapid reduction in strength of association outside that 
region. It suggests that the primary associated variant(s) lies in that interval [Pimentel-Santos 
et al., 2009]. In TASC study an imputation analysis was performed to narrow the likely region 
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of association. The strongest association was seen with rs11465817, which lies in intron 9, 
and with rs11209026 (which codes for Gln381Arg substitution), in exon 9. Curiously, our 
Portuguese study did not demonstrate any protective effect against AS for the Arg381Gln 
SNP (rs11209026) in the IL23R gene, which is consistent with the Alberta Canadian 
population. This apparent lack of concordance may be due to the different ethnical 
backgrounds studied, or represent a type II error, given the modest power of the Portuguese 
study to detect association with this rare, protective SNP. Recently, two definite SNPs in 
IL23R, rs11209026 and rs11209032 were identified in association with AS [Evans et al., 
2011]. Interestingly, rs11209026 was not polymorphic in the Asian population, which may 
explain the lack of association between common variants in IL23R and AS in this population. 
IL23R is also known to be associated with IBD [Duerr et al., 2006; Dubinsky et al., 2007], 
psoriasis [Cargill et al., 2007; Wu et al., 2010], and psoriatic arthritis [Rahman et al., 2008; 
Bowes & Barton et al., 2010] including the juvenile-onset psoriatic arthritis [Hinks et al., 
2011], which partly explains the frequent coexistence of these pathologies in individual cases 
and families.  
The IL23R association with AS was the first suggestion that TH17 lymphocyte pathway may 
be involved in disease pathogenesis. Data supporting an increase in TH17 lymphocytes 
numbers in AS [Jandus et al., 2008], and an increase of serum IL17 levels [Wendling et al., 
2007], pinpoint a role for these cells. Moreover, other related genes in the IL23R pathway 
have also been implicated in AS, such as Signal Transducer and Activator of Transcription 3 
(acute-phase response factor) (STAT3) [TASC, 2010], Janus kinase 2 (JAK2) [TASC, 2010], 
IL12B [Danoy et al., 2010], CARD9 [TASC, 2010; Pointon et al., 2010a], and PTGER4 
[Evans et al., 2011]. STAT3 is a key transcription factor in IL23R signaling; JAK2 encodes 
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the partner of STAT3 in this pathway. Both of them are also associated with IBD [Barrett et 
al., 2008]. IL12B encodes IL-12p40, a component of the heterodimeric cytokines, IL-12 and 
IL-23. CARD9 encodes a component of the Dectin-1 involved in innate immunity, by 
recognizing β-glucan, a component of fungal and some gram-negative bacteria cell wall 
which promote the activation of TH1 and TH17 lymphocytes, thereby linking the innate and 
adaptive immune systems [LeibundGut-Landmann et al., 2007]. PTGER4 encodes the 
PGE2EP4 receptor, one of the four known PG2E receptors (named EP1-4), which have 
several effects and are expressed in several tissues. In response to β glucan recognition, PGE2 
is produced, and the interaction with PGE2EP4R stimulates dendritic cell production of IL-23 
leading to TH17 activation [Chen et al., 2010]. In collagen-induced arthritis the inhibition of 
PGE2EP4, in both prophylactic and therapeutically models, has shown to attenuate the 
inflammatory process [Chen et al., 2010]. Another interesting point is the link between 
inflammation and new bone formation, promoted by PGE2EP4, which seems relevant in AS 
pathogenesis. Repetitive mechanical stress has been shown to up regulate PGE2 production 
and in turn new bone formation at entheses [Zhang & Wang, 2010]. Therefore there is some 
evidence that non-steroidal anti-inflammatory drugs, which inhibit PGE2 production, may 
reduce bone formation in AS [Wanders et al., 2005a, 2005b]. 
All this knowledge changed the way of thinking about AS pathogenesis and promoted the 
development of new potential therapies. Interesting results have been documented with 
Ustekinumab, an anti-IL12p40 antibody targeting the shared IL-23/IL-12 subunit, in psoriasis 
[Kauffman et al., 2004; Toichi et al., 2006], psoriatic arthritis [Kavanaugh et al., 2010; Zhu et 
al., 2010], and Crohn’s disease [Mannon et al., 2004; Fuss et al., 2006]; no data is available 
yet to asses the effect of Ustekinumab in AS. Secukinumab (AIN457), another fully human 
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monoclonal antibody targeting IL-17A, demonstrated preliminary efficacy in psoriasis 
[Hueber et al., 2010; Kurzeja et al., 2011] and in non-infectious AAU [Hueber et al., 2010]. 
Preliminary data has shown that this agent may be useful in the treatment of moderate to 
severe active AS [Baeten et al., ACR 2010].  
 
3.2.4.3. ANKH 
 
Conflicting results regarding ANKH association with AS have been published. Our study and, 
another previous one, of ANKH showed no association with susceptibility to AS [Timms et 
al., 2003; Pimentel-Santos et al., 2012a]. However, weak positive findings have also been 
reported by some authors [Furuichi et al., 2008], and it has been suggested that this 
association may be more strongly observed in women [Tsui et al., 2005]. ANKH variants 
studied in our Portuguese population did not seem to exert any influence in either men or 
women [Pimentel-Santos et al., 2012a]. Furthermore, no association has been identified with 
this gene in GWAS in AS until now, which suggests ANKH may not be a major determinant 
of susceptibility to AS [Burton et al., 2007; Evans et al., 2011; TASC, 2010]. 
ANK is a multipass transmembrane protein encoded by ANKH gene that regulates cellular 
inorganic pyrophosphate (PPi) export across the plasma membrane to the extracellular 
compartment. The interest in this gene is therefore related to the potential effect in bone 
metabolism. A loss-of-function mutation in the homologous gene, ank, in a mice model, is 
associated with the development of severe ectopic mineralization and skeletal ankylosis, 
resembling AS [Ho et al., 2000]. Humans with gain-of-expression polymorphisms in this 
gene develop calcium pyrophosphate chondrocalcinosis [Williams et al., 2002; Zhang et al., 
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2005], whereas loss-of-function polymorphisms cause excess hydroxyapatite deposition as 
seen in Jackson’s craniometaphyseal dysplasia [Numberg et al., 2001; Reichenberger et al., 
2001]. For all the above-mentioned aspects, it was hypothesized that ANKH polymorphisms 
may contribute to spinal ossification in AS; such an effect would lead to changes in BASMI 
and mSASSS scores. However ANKH variants studied in our research didn’t seem to have 
any significant association with these scores [Pimentel-Santos et al., 2012a]. It seems, thus, 
that ANKH polymorphism is not a major determinant of susceptibility to AS and does not 
have a major influence on disease severity (as measured by BASMI and mSASSS) - at least in 
Portuguese population.  
Most of published studies lacked power. This might account for conflicting results 
encountered in literature and further research is needed in order to reach definitive 
conclusions. 
 
3.2.4.4. TNFSF8  
 
A genome-wide linkage screen, performed in multiple cases of SpA families, identified a 
highly significant linked region on chromosome 9q31-34, named SPA2 [Miceli-Richard et al., 
2004]. This locus overlaps one of those previously identified in the first two studies of 
genome-wide linkage scans in AS [Brown et al., 1998a; Laval et al., 2001]; furthermore, 
meta-analysis of all published linkage scans also supports a linkage of SPA2 and SpA [Carter 
et al., 2007]. It was estimated that this locus, comprising about 85 genes, might contain major 
predisposition gene(s), accounting for 20-25% of the non-MHC genetic susceptibility to SpA 
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[Breban et al., 2006]. To add, SPA2 represents one of the three regions paralogous to the 
MHC [Said-Nahal et al., 2002].  
Systematic LD mapping of the whole SPA2 region using a dense set of tag-SNPs refine the 
peak association to an interval with a 6-SNPs haplotype spanning 40 kb and located between 
C9ORF91 and TNFSF15; rs6478105 was the strongest individual associated SNP [Zinovieva 
et al., 2009]. In our recently published study another significant association with SNP 
rs3181357 lying in the SPA2 locus was identified in a French cohort and subsequently 
replicated in an independent combined Belgian and Portuguese cohort [Zinovieva et al., 
2011].  
TNFSF15 and TNFSF8 are members of the TNF superfamily of genes that are lying in the 
SPA2 locus [Franke et al., 2010]. TNFSF8, codes for CD30L (CD153), a TNF superfamily 
ligand expressed on activated CD4+ T cells, antigen-presenting cells and neutrophils, which 
interacts with CD30 on effectors or memory Th cells. CD30L/CD30 signaling seems to play a 
role in Th17 cell differentiation in vitro and in vivo [Sun et al., 2010]. TNFSF15 has been 
shown to stimulate TH17 lymphocytes proliferation [Pappu et al., 2008]; in an inflammatory 
colitis mouse model, TNFSF15 up regulates TH1 and TH17 lymphocytes activity [Takedatsu 
et al., 2008]. Both, TNFSF8 [Sun et al., 2008] and TNFSF15 [Franke et al., 2010; Yamazaki 
et al., 2005] may have a role in IBD. However, no association was seen with TNFSF8 neither 
with TNFSF15 in others studies performed in AS cases [Burton et al., 2007; TASC, 2010, 
Evans et al., 2011]. Thus, it is not known if TNFSF8 or TNFSF15 SNPs described as 
associated with SpA are directly implicated in SpA predisposition, either alone or in 
combination with other polymorphisms located in this same region. Alternatively, it could be 
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a surrogate for one or several other variant(s) not yet identified, by means of LD. Further 
studies will be required to clarify all these issues. 
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3.3. LESSONS FROM GENOMIC PROFILING IN ANKYLOSING SPONDYLITIS 
 
3.3.1. Applications of microarrays in rheumatology/spondyloarthritis 
 
Several microarrays studies have been published looking at SpA. A number of early studies 
used different tissue sources and smaller microarrays with whole-genome arrays prohibitively 
expensive [Thomas & Brown, 2010a, 2010b]. The first study in 2002 identified genes more 
highly expressed in peripheral blood mononuclear cells (PBMC) of patients with 
spondyloarthropathy (SpA), rheumatoid arthritis (RA) and psoriatic arthritis (PsA), in 
comparison to normal subjects [Gu et al., 2002a]. A 588-gene microarray was used as a 
screening tool and the results were validated by reverse transcription-polymerase chain 
reaction (RT-PCR). A total of 16 genes were identified encoding differentiation markers, 
cytokines, cytokine/chemokine receptors and signaling and adhesion molecules. An increased 
expression of Chemokine (C-X-C motif) receptor type 4 (CXCR4) and its ligand Stromal cell-
derived factor-1 (SDF-1), in synovial fluid mononuclear cells (SFMC), were seen in all three 
arthritis groups. The conclusion was that the CXCR4/SDF-1 is a potential pro-inflammatory 
axis for SpA, PsA and RA. However no genes were identified that could discriminate between 
the different diseases. 
In another study gene expression profiles of SFMC from SpA and RA patients were compared 
with PBMC of healthy controls to evaluate the unfolded protein response (UPR) hypothesis 
and identify which cytokines/chemokines were being expressed and which cell fractions were 
involved. An 1176-gene microarray was used and the results were validated by RT-PCR. 
There was an increase in transcripts encoding Monocyte chemotactic protein-1 (MCP-1), 
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proteasome subunit C2 and Binding immunoglobulin protein (BiP), which suggest the 
existence of an UPR. BiP was higher in SpA SFMC compared to RA SFMC and macrophages 
were identified as the potentially cell type involved [Gu et al., 2002b]. 
A third study identified a gene expression profile in gut biopsies that could differentiate SpA 
patients with sub-clinical gut inflammation from SpA patients without gut disease. 2625 
differentially expressed sequence tags were initially identified through macroarrays in colon 
biopsies from Crohn’s and SpA patients which were then used to construct a microarray 
which was sued to screen a further sample cohort. Ninety five expressed sequence tags 
clustered patients with Crohn’s and those with SpA and chronic gut inflammation [Laukens et 
al., 2006].  
This topic of the discussion will be focused on studies using peripheral blood and microarray 
platforms covering the whole genome. The results seem to be quite heterogeneous reflecting 
the different methodologies involved, as commented above. Several aspects, summarized in 
Table 5, may introduce variability and bias in the results, specifically; 
a) Patient selection: numbers of patients, the criteria used to classify and include 
the patients, different degrees of activity/severity of the disease and patients 
receiving different therapies are examples of heterogeneity that might influence 
the final results. 
b) Cell Source used for analysis: PBMC vs. whole blood or a specific cell subset. 
c) Differences in microarray platform technology and data analysis tools. 
d) Differences in methodology used regarding validation of candidate biomarkers. 
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Based on seven papers published since 2007, several pathways relevant to potential SpA 
pathological processes have been identified. Moreover, potential biomarkers with applications 
to diagnosis and treatment response prediction in clinical practice were also flagged. Table 5, 
summarizes the similarities and methodological differences between the studies and 
reinforces the caution that should be observed when translating these findings to clinical 
practice. All the knowledge obtained must be interpreted as hypotheses which need validation 
in future studies. 
 
 
Table 5: Comparison between published microarray studies in SpA context. 
 
 
 Subjects Criteria Samples Microarray Validation 
Smith et al. 2008 
6AS+2uSpA 
9HC 
mNYC 
ESSG, Amor 
Macrophage Affymetrix qPCR 
Haroon et al. 
2010 
16AS mNYC PBMC Affymetrix qPCR 
Sharma et al. 
2009 
11uSpA+7uSpA+25HC 
Likelihood 
Score 
Whole blood Affymetrix 
Microarrays 
(2 set) 
Duan et al. 2010 
18AS+18HC 
35AS+18HC 
mNYC PBMC Illumina qPCR 
Gu et al. 2009 
21AS+28uSpA 
23AS+18uSpA 
26HC+12RA+5LBP 
Calin PBMC Illumina qPCR 
Assassi et al. 2011 
16AS + 14HC+ 
SLE+SSC 
27AS+27HC 
mNYC Whole bood Illumina qPCR 
Santos et al. 2011 
18AS+18HC 
78AS+78HC 
mNYC Whole blood Illumina qPCR 
AS: Ankylosing spondylitis; SpA: Spondyloarthritis; HC: Healthy controls; RA: Rheumatoid arthritis; LBP: Lumbar back pain; SLE: 
Systemic lupus erythematosus; SSC: Systemic Sclerosis; mNYC: modified New York criteria; ESSG: European Spondyloarthropathy 
Study Group; PBMC: Peripheral blood mononuclear cells; qPCR: Quantitative reverse transcription polymerase chain reaction. 
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3.3.2. The link between an abnormal innate immune response and Ankylosing 
Spondylitis 
 
One of the most intriguing aspects regarding AS pathogenesis is the possible link between 
pathogens and disease onset. There are several pieces of evidence that an abnormal host 
response against pathogens is implicated in AS and/or SpA pathogenesis. Sixty percent of 
patients with SpA without diagnosed Crohn’s disease evidenced endoscopic or histological 
signs of gut inflammation [Mielants et al., 1995]. Moreover, studies showing HLA-B27 
transgenic rats do not develop inflammatory intestinal or peripheral joint disease in a germ-
free environment support a role of commensal gut flora in the shared pathogenesis of gut and 
joint manifestations [Taurog et al., 1994]. 
Pattern recognition receptors (PRRs) in innate immune cells play a pivotal role in the first line 
of the host defense system. These receptors are transmembrane receptors such as Toll-like 
receptors (TLRs) or C-type lectin receptors (CLRs) and cytosolic receptors RIG-I-like 
receptors (RLRs) and NOD-like receptors (NLRs) [Jeong & Lee, 2011]. Interestingly, 
expression changes in genes involved in innate immune response such as TLRs [Assassi et al., 
2011], NLR family, pyrin domain containing 2 (NLRP2) [Sharma et al., 2009] and C-type 
lectin domain family 4, member D (CLEC4D) [Pimentel-Santos et al., 2011] were 
consistently observed in several different studies using microarray technology (Fig 3).  
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Figure 3: Possible functional effects between innate immune receptors and AS candidate 
genes (Adapted from Thomas & Brown, 2010a). 
 
  
TLRs are characterized by an extracellular leucine-rich repeat (LRR) domain, a 
transmembrane domain and a cytoplasmic Toll/IL-1R (TIR) domain. As many as 13 TLRs 
family members have been identified in mammalian systems with TLRs 1 to 10 expressed in 
humans. They can be divided into 2 groups according to cellular localization and respective 
ligands. TLRs 1, 2, 4, 5, and 6, are expressed on the cell surface and recognize microbial 
components in the outer membrane of bacteria. TLRs 3, 7, 8 and 9 are found in intracellular 
vesicles and recognize microbial nucleic acids [Sirisinha, 2011]. TLRs are expressed in 
various immune (monocytes, macrophages, dendritic cells, B cells) and non-immune 
(epithelial cells, endothelial cells, fibroblasts) cells. TLR4 was overexpressed in SpA patients 
in peripheral whole blood cells, assessed by microarray [Assassi et al., 2011; Pimentel-Santos 
et al., 2011], in PBMCs, measured by flow cytometry [de Rycke et al., 2005] and in 
DISCUSSION AND CONCLUSIONS 
  
 
169 
 
lymphocytes, monocytes and neutrophils by qPCR [Yang et al., 2007]. The main ligand for 
TLR4 is lipopolysaccharide (LPS) in the outer membrane of Gram-negative bacteria however 
it also recognizes other exogenous pathogens such as mannan from Candida albicans, 
glycoinositolphospholipid from Trypanosoma, and the envelope proteins from mouse 
mammary tumor virus (MMTV) and respiratory syncytial virus (RSV). It also recognizes 
some endogenous molecules, including HSP (HSP60, HSP70, and HSP gp96), fibrinogen, 
oligosaccharides of hyaluronic acid, extracellular domain A of fibronectin, heparan sulfate, 
myeloid-related proteins (Mrp8 and Mrp14), oxidized LDL, saturated fatty acid and amyloid-
β [Jeong & Lee, 2011]. Microarray analysis also showed overexpression of TLR5 in 
peripheral whole blood cells from SpA patients [Assassi et al., 2011; Pimentel-Santos et al., 
2011].  Flagellin, a primary component of Gram negative bacteria flagella, is the main ligand 
for TLR5 [Hayashi et al., 2001], which is mainly expressed on the luminar surface of 
epithelial cells in the mucosal tissues and respiratory tract [Gewirtz et al., 2001]. 
The wide responsiveness of TLRs to a wide variety of external and internal signals, and the 
link that these receptors establish between the innate and adaptative immune systems, 
reinforces the theory that TLRs are strongly implicated in the development of chronic 
inflammatory diseases. However, mechanistic studies are needed in order to clarify the role of 
specific receptor subtypes in AS development.  
Members of the NLRs family consist of a central nucleotide-binding and oligomerization 
(NACHT) domain, which is commonly flanked by C-terminal LRRs domain and N-terminal 
CARD or pyrin (PYD) domains [Schroder & Tschopp, 2010]. So far, 20 NLR family 
members have been identified in humans. Two main subgroups have been described. One, 
including NODs (NOD 1-5 and CIITA), detects pathogen-associated molecular patterns 
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(PAMPs) existing in Gram-negative bacteria cell walls and elicit responses that are distinct 
from those of the TLRs. The other NLR subgroup involves a large family of molecular 
complexes known as the “inflammasomes”, the NLRPs (NLRP1-14) and the IPAF subfamily, 
consisting of IPAF and NAIP [Fitzgerald, 2010; Schroder & Tschopp, 2010]. The 
inflammasomes are macromolecular cytosolic complexes composed of several proteins, some 
of which are found in all inflammasomes (pro-caspase-1, Apoptosis-associated Speck-like 
Protein Containing a Caspase Recruitment Domain-ASC), and others which are present 
depending on the inflammasome type (cardinal, pro-caspase-5, domain with function to find-
FIIND). These complexes are involved in the innate immune response recognizing both 
endogenous signals (adenosine triphosphate, urate, and calcium pyrophosphate crystals) as 
well as external pathogen-derived products (bacterial RNA, bacterial toxins) [Drenth & van 
der Meer, 2006].  
As such, the reduced expression of NLRP2 in AS was a very interesting observation [Sharma 
et al., 2009]. NLRP2, as with other NLRs, induces an inhibition of the NF-kB gene, leading to 
regulation of IL1β, a relevant cytokine in the disease process. The downregulation of NLRP2 
may therefore lead to upregulation of IL-1β. Supporting this, polymorphisms in NLR genes 
have also been implicated in Behçet’s disease and Crohn’s disease which share some clinical 
features with AS [Kappen et al., 2009; Cummings et al., 2010]. Another interesting point is 
the association of CARD9 with Crohn’s disease and AS [Pointon et al., 2010a] which has a 
pivotal role in NOD2 signaling. 
Another family of receptors of particular interest is the C-type lectins which display a distinct 
protein domain, the carbohydrate recognition domain (CRD). Based on the organization of 
their CRDs, 17 distinct groups have been defined [Drickamer & Fadden, 2002; Zelensky & 
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Gready, 2005]. While some recognize DAMPs which facilitate adhesion between cells, 
adhesion of cells to extracellular matrix and other non-enzymatic functions, others may act as 
PRRs [Graham & Brown, 2009] after PAMP recognition. Upon ligand biding, CLRs can 
induce a variety of cellular responses, and can be functionally divided into those that inhibit 
or those that induce cellular activation. In general, inhibitory receptors contain a consensus 
immunoreceptor tyrosine-based inhibitory motif (ITIM) in their cytoplasmic domains, while 
activation receptors either contain an immunoreceptor tyrosine-based activation motif 
(ITAM), or associate with signaling adaptor molecules. Depending on whether signaling is 
through ITAM or ITIM , either activation of Src homology 2 (SH2) domain-containing 
protein tyrosine kinases (SyK, ZAP 10) or SH2 containing-phosphatases (SHP-1, SHP-2) are 
recruited, thereby up or downmodulating cellular activation, respectively [Long, 1999; 
Majeed et al., 2001]. 
Genes encoding each family are distinctly clustered in the telomeric Natural Killer-gene 
complex (NKC), on chromosome 12. The Dectin-1 cluster of receptors includes Dectin-1, 
lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1), C-type lectin-like receptor-1 
(CLEC-1), CLEC-2, CLEC12B, CLEC9A and myeloid inhibitory C-type lectin-like receptor 
(MICL). The Dectin-2 cluster of receptors includes Dectin-2, DCIR, DCAR, BDCA-2, Mincle 
and CLEC4D [Graham & Brown, 2009]. 
Dectin-1, is expressed in dendritic cells, monocytes, macrophages, neutrophils and weakly in 
a subset of T cells, B cells and eosinophils. It recognizes fungal β-glucan, working as an 
activating receptor uniquely possessing an ITAM in the cytoplasmic domain. The induction of 
phagocytosis, production of reactive oxygen species and cytokine production is mediated by 
DISCUSSION AND CONCLUSIONS 
  
 
172 
 
NF-kB and spleen tyrosine kinase (Syk). In addition, some of these effects require cooperation 
with MyD88-mediated TLR signaling [Kanazawa, 2007]. 
Dectin-2 and Mincle are expressed in macrophages, dendritic cells and weakly in Langerhans 
cells and monocytes. The receptors recognize several pathogens (Candida albicans, 
Saccharomyces cerevisiae, Mycoplasma tuberculosis, Histoplasma capsulatum) but also 
endogenous ligands. Both have characteristic short cytoplasmic domains and are associated 
with FcRγ domains. Their activation, inducing the production of proinflammatory cytokines, 
is mediated by Syk- and CARD9-dependent pathways but independently of MyD88-mediated 
TLR signaling [Graham & Brown, 2009].  
CLEC4D has been found to be expressed in a monocyte/macrophage restricted manner, and 
although no ligand or biological function has as yet been described, the receptor has been 
shown to be upregulated at the transcript level in a number of disease settings, similarly to 
two other members of the family, Mincle and Dectin-2. They are able to recognize and 
promote pathogen clearance and induce inflammatory signals. This process seems to follow 
the Syk and CARD9 pathway which was recently implicated in a mouse model of SpA 
[Ruutu et al., 2010]. The upregulation of CLEC4D, observed for the first time in an 
expression profiling study of AS patients [Pimentel-Santos et al., 2011], supports the 
importance of innate immune mechanisms in AS pathology. However, further studies are 
required to confirm this hypothesis. 
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3.3.3. Proinflammatory vs. immunosuppressive signatures 
 
Transcriptional profiling studies have demonstrated that transcripts involved in the 
inflammatory response were differentially expressed in AS patients and controls, but reports 
on the nature of these changes seem to vary. A proinflammatory profile in PBMCs, from 
uSpA and AS, is indicated by an increased expression of regulator of G-protein signaling 1 
(RGS1), Nuclear receptor subfamily 4, group A, member 2 (NR4A2), Heparin-binding EGF-
like growth factor (HBEGF) and suppressor of cytokine signaling 3 (SOCS3), in both groups 
[Gu et al., 2009]. However, other reports suggest decreased immune responsiveness such as a 
“reverse Interferon-gamma (IFNγ) signature” [Smith et al., 2008], and immunosuppressive 
phenotypes [Duan et al., 2010; Pimentel-Santos et al., 2011]. The main reason for these 
differences in the transcriptomic profiles, between the first study and the 3 later studies, is 
unknown but differences in patients and methodologies may contribute.  
IFNγ dysregulation in AS is supported by previous studies of cytokines expression. A lower 
frequency of IFNγ positive T cells has been reported in AS patients [Rudwaleit et al., 2001] 
and gut biopsy samples show a reduced TH1 profile in lymphocytes from SpA patients [van 
Damme et al., 2001]. Moreover, IFNγ is expressed at lower levels in synovium from SpA 
compared to rheumatoid arthritis patients [Canete et al., 2000]. This knowledge may 
contribute to understanding AS pathogenesis as decreased IFNγ production by macrophages 
could impair the host’s ability to clear pathogenic organisms. Recent studies support this 
theory [Rothfuchs et al., 2001; Inman et al., 2006], and may implicate arthritogenic organisms 
in AS susceptibility. In addition, IFNγ reduction, can contribute to activation of the IL-23/IL-
17 axis a major axis in AS pathogenesis.  
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Complementary to the report in macrophages from peripheral blood of AS patients [Smith et 
al., 2008], two different studies, from PBMCs and whole blood, have shown an 
immunosuppressive phenotype [Duan et al., 2010, Pimentel-Santos et al., 2011]. The first one 
validated three downregulated genes, NR4A2, Tumor necrosis factor, alpha-induced protein 3 
(TNFAIP3) and CD69 molecule (CD69). NR4A2 has been associated with T-cell subset 
communication and the macrophage inflammatory response. TNFAIP3 serves as negative 
feedback system for the TNFα induced by NF-kB, acting as an anti-inflammatory molecule to 
control prolonged inflammation. CD69 is an early leukocyte activation molecule expressed at 
sites of active inflammation. Of further interest were the results of Ingenuity Pathways 
Analysis using the differentially expressed gene set showing altered activity of the 
JAK/STAT signaling pathway in AS patients [Duan et al., 2010]. Both STAT3 and JAK2 have 
been shown to be genetically associated with IBD and AS [Barrett et al., 2008; Danoy et al., 
2010; Evans et al., 2011], and represent key downstream molecules of the IL-23/IL-17 
pathway [Ma et al., 2008].  
In the second study downregulation of several pro-inflammatory genes were described 
highlighting another aspect of AS pathogenesis [Pimentel-Santos et al., 2011]. Protein 
tyrosine phosphatase, non-receptor type 1 (PTPN1) and Dedicator of cytokinesis 10 
(DOCK10), which are both involved in mediating IL4 actions [Paul & Ohara, 1987] were 
downregulated. Protein tyrosine phosphatase 1B (PTP1B), the PTPN1 protein product, is a 
ubiquitously expressed enzyme shown to negatively regulate multiple tyrosine 
phosphorylation-dependent signaling pathways, including the downstream processes involved 
in CLRs activation [Long, 1999; Majeed et al., 2001] and IL4 signaling [Lu et al., 2008]. 
Dock10 is also regulated by IL4 in B cells [Yelo et al., 2008]. This is of particular interest as 
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IL4 may play a role in AS pathogenesis. Interleukin 4 (IL4) has a variety of stimulatory and 
inhibitory actions on B and T cells [Jelinek & Lipsky 1988; O’Garra et al., 1988; Rousset et 
al., 1988]. Recent studies have also indicated a potential role for IL4 producing CD8+ T cells 
in the pathogenesis of AS. Although CD8+ T cells are predominately associated with the 
production of ‘TH1’ cytokines, such as IFNγ, there is now good evidence that some subsets of 
these cells can also produce ‘TH2’ cytokines such as IL4, IL5 and IL10 [Baek et al., 2008]. 
The potential functions associated with IL4-producing CD8+ T cells are as yet unclear but the 
subtype CD8+/TCR αβ+ T cells, with a regulatory phenotype and function (expressing 
CD25+, CTLA4+, Foxp3+, but negative for IFNγ and perforin), were previously described in 
peripheral blood of AS patients [Jarvis et al., 2005]. These results were confirmed in a recent 
study suggesting an altered pattern of CD8+ T cell differentiation in AS and in HLA-B27+ 
healthy individuals. This predisposition to generate IL4+CD8+ T cells may play a role in 
pathogenesis of SpA [Zhang et al., 2009]. Further supporting this theory, RUNX3 was 
identified as a candidate gene in a GWAS [TASC, 2010]. The association of RUNX3 with AS 
provides additional evidence of a role for CD8+ T cells in the disease. Its expression in 
immature lymphocytes is triggered by IL7R signaling, leading to suppression of CD4 and 
upregulation of CD8 expression [Park et al., 2010]. 
Although there are some differences between the different expression profiling studies, their 
findings do contribute to a greater understanding of the pathogenesis of AS, particularly in the 
delineation of the roles of the innate and adaptive immune responses.  
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3.3.4. Bone ossification and resorption processes 
 
Bone formation and bone loss take place at sites closely located to each other presenting an 
“apparent paradox”, which is reflected in the changes in bone and cartilage metabolism 
occurring in the AS disease process [Carter & Lories, 2011]. Ossification is the hallmark of 
AS and has been linked to aberrant activation of bone morphogenic protein (BMP) and 
wingless (WNT) signaling. Bone resorption, driven by the impact of inflammation on the 
bone remodeling cycle, occurs simultaneously, with up to 56% of patients becoming 
osteopenic and some of them osteoporotic [Lange et al., 2005].  
Biomarkers, reflecting structural damage and disease activity, constitute a high priority for the 
understanding of the pathogenesis of AS and for the new therapy discovery. Two microarray-
based studies have contributed to the improvement of knowledge in this field. A bone 
remodeling signature was described associated with an overexpression of BMP6, Proprotein 
convertase subtilisin/kexin type 6 (PCSK6), Kringle containing transmembrane protein 1 
(KREMEN1) and Catenin (cadherin-associated protein) alpha-like 1 (CTNNAL1) genes in 
SpA patients [Sharma et al., 2009].  
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Figure 4: The canonical WNT signaling pathway (adapted from Carter & Lories, 2011). 
 
KREMEN1 and CTNNAL1 are negative regulators of WNT/catenin pathway via dickkopf 
homolog 1 (DKK1), or by direct inhibition of β-catenin, respectively (Fig 4). Although four 
different intracellular pathways can be triggered upon WNT receptor interaction, the WNT/β-
catenin or “canonical” pathway is of particular interest in bone and cartilage biology. This 
pathway involves the interaction of WNT ligands with frizzled (FZD) receptors and low-
density lipoprotein receptor-related protein 4, 5 or 6 (LRP 4, 5 or 6) co-receptors. In the 
absence of a WNT-FZD-LRP 4/5/6 interaction, cytoplasmic β-catenin is captured within a 
destruction complex comprising adenomatous polyposis coli (APC), axin, glycogen synthase 
kinase 3β (GSK-3β), and casein kinase 1α (CK1 α). The kinases phosphorylate β-catenin, 
which leads to ubiquitinylation and subsequent destruction in a proteasome complex. When 
WNT does complex with FZD and LRP 4/5/6, axin binds to the cytoplasmic tail of LRP5 or 
6, thereby phosphorylating and inhibiting GSK-3β [Gordon & Nusse, 2006]. This process 
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enables cytoplasmic β-catenin accumulation which then translocates to the nucleus, where it 
interacts with transcription factor (TCF)/lymphoid enhancer factor (LEF) family members and 
modulates WNT target genes expression [Gordon & Nusse, 2006]. Several proteins that are 
not involved in β-catenin stability can also regulate β-catenin signaling. One example is the 
direct association of α-catenin with β-catenin in the nucleus which interferes with protein-
DNA interactions required for TCF-mediated transcription [Giannini et al., 2000]. In addition, 
different endogenous antagonists inhibit WNT signaling; DKK1 and sclerostin (SOST). 
DKK1 acts by direct binding to and inhibiting the WNT co-receptor LRP6. The related 
DKK2, however, can function either as LRP6 agonist or antagonist, depending on the cellular 
context, suggesting that its activity is modulated by unknown co-factors. In this context, the 
transmembrane proteins KREMEN1 and -2 were recently identified as additional DKK 
receptors, which bind to both DKK1 and DKK2 with high affinity [Mao & Niehrs, 2003]. It 
was shown that DKK1 was able to simultaneously bind to LRP5/6 and KREMEN and that the 
ternary complex was rapidly endocytosed, thus preventing the WNT-LRP interaction. The 
interaction with KREMEN seems not to be essential, but it plays a role in facilitating DKK-
mediated antagonism if the level of LRP5/6 is high [Wang et al., 2008]. The upregulation of 
KREMEN1 and CTNNAL1 genes by these mechanisms can compromise bone formation. In 
contrast, upregulation of BMP6 and its regulator PCSK6 can contribute to the AS ossification 
process. BMPs are members of the transforming growth factor- β (TGF β) superfamily, play a 
crucial role in embryonic development, cell lineage determination, and osteoblastic 
differentiation and function. Enthesitis, a distinctive feature of SpA, is associated with 
heterotopic cartilage and bone formation (enthesophyte) [Benjamin & McGonagle, 2001]. 
Different BMPs are expressed in distinct stages of ankylosing enthesitis shown in the DBA/1 
mouse model. BMP2 is found in proliferating cells and entheseal cells committing their 
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differentiation fate to chondrogenesis. BMP7 is recognized in prehypertrophic chondrocytes 
and BMP6 in hypertrophic chondrocytes [Lories et al., 2005]. Several regulators of 
endochondral bone formation with different effects in different stages were described 
[Kronenberg, 2003]. It is therefore possible that the presence of progenitor cells at the 
entheseal site promotes bone formation in SpA patients. Activation of the BMP signaling 
pathway (phosphorylated Smad1/5) was found in cells at the sites of entheseal inflammation 
in patients with AS [Lories et al., 2005]. 
Another bone remodeling signature was identified in association with a downregulation of 
Sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 2 (SPOCK2), E1A 
binding protein p300 (EP300) and protein phosphatase 2, regulatory subunit A, alpha 
(PPP2R1A) in AS, which are possible mediators in the ossification process [Pimentel-Santos 
et al., 2011].  
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Model representing the effects of SPARC on marrow mesenchymal progenitors 
(adapted from Delany & Hankenson, 2009). 
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SPOCK2, also known as Sparc/osteonectin, is a non-collagenous bone protein. It is a member 
of the matricellular class of glycoproteins which includes periostin, tenascin C, osteopontin, 
bone sialoprotein, thrombospondin-1 and thrombospondin-2 [Alford & Hankenson, 2006]. It 
has been hypothesized to play a role in the regulation, production, assembly and maintenance 
of the matrix turnover in cartilage [Hausser et al., 2004; Gruber et al., 2005]. In this process 
TGFβ and IFNγ exert antagonistic effects, and play important role in the physiologic 
regulation of extracellular matrix turnover. In fact, the TGFβ gene positively regulates pro-
alpha2 chain of type I collagen (COL1A2) through the Smad signal transduction pathway, 
whereas IFNγ inhibits COL1A2 through Stat1. Additionally, PPP2R1A also downregulated in 
AS [Pimentel-Santos et al., 2011], is thought to mediate TGFβ regulation through Smad 
[Heikkinen et al., 2010]. Animal models using SPARC-null mice have provided excellent 
information on the function of this protein in bone. SPARC-null mice develop profound low-
turnover osteopenia (bone loss), associated with decreased numbers of osteoblasts and 
osteoclasts, and a markedly decreased bone-formation rate [Delany et al., 2000; Boskey, 
2003]. Moreover SPARC-null mice have decreased trabecular bone volume due to decreased 
trabecular number [Machado dos Reis et al., 2008] and an increase in extra-skeletal adipose 
deposits [Mansergh et al., 2007]. In vitro studies showed accumulation of SPARC during 
early osteoblastic differentiation, likely in association with collagen matrix, which decreases 
as the cells acquire more osteoblastic characteristics. This expression pattern seems 
appropriate because SPARC regulates collagen fibril assembly, and matrix is abundantly 
deposited in the earlier stages of differentiating cultures. SPARC has a positive effect on 
maintaining and expanding the mesenchymal progenitor pool, and promotes 
osteoblastogenesis/osteoblast function and decreases adipogenesis (Fig 5) [Delany & 
Hankenson, 2009]. Expression of SPARC by osteoclasts has not been reported. Therefore, the 
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mechanisms by which SPARC limits osteoclast formation may involve the direct interaction 
with osteoclasts or osteoclast precursors through the bone matrix, and/or the effect of SPARC 
on immune cells, marrow stromal cells, and osteoblasts supporting osteoclast development 
[Machado do Reis et al. 2008]. In summary, recent findings supports the idea that SPARC 
play a critical role in regulating bone remodeling and maintaining bone mass. Thus its 
dysregulated expression may contribute to the aberrant matrix formation in AS. 
Interestingly, the protein produced by EP300 belongs to the group of nuclear p300/CBP 
transcriptional coactivators for both Smad3 and Stat1a that integrate signals that positively or 
negatively regulate COL1A2 transcription [Ghosh et al., 2001]. Transactivated p300, 
controlled by phosphoinositide-3 kinase (PI3K)/AKT, is also an important transcriptional co-
activator of Sox9, which modulates the expression of the major extracellular matrix 
component, aggrecan [Cheng et al., 2009]. Moreover, there is some evidence supporting a 
p300 interaction with the Wnt pathway as it is a β-catenin transcriptional coactivator. 
Downregulation of these genes might lead to a loss of matrix integrity thereby accelerating 
tissue damage. This may be reinforced by a pro-inflammatory status associated with 
downregulation of EP300 [Ahmad et al., 2007]. 
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3.3.5. Biomarkers for early diagnostic purposes 
 
Low back pain (LBP) is a very common symptom, responsible for 3% of annual medical 
visits in the USA [Licciardone, 2008]. However only 5% of the chronic back pain seen in 
general practice designated as “inflammatory”, is associated with SpA [Underwood & Dawes, 
1995]. To classify patients with AS or SpA, various criteria sets can be used. The modified 
New York Criteria [van der Linden et al., 1984a] for AS, the Amor criteria [Amor et al., 
1990] and the European Spondyloarthropathy Study Group (ESSG) criteria [Amor et al., 
1991], developed in the 1990s, before magnetic resonance imaging (MRI) was available, 
addressed all SpA subtypes. Recently, it has been proposed to divide SpA patients into 
subgroups according to clinical presentation. The Assessment of SpondyloArthritis 
International Society (ASAS) group has developed criteria to classify patients with axial SpA 
with or without radiographic sacroiliitis, and patients with predominant peripheral SpA 
[Rudwaleit et al., 2009b, 2009c; Rudwaleit, 2010a, 2010b]. With a sensitivity of 82.9% and a 
specificity of 84.4% , these axial SpA criteria perform better than the ESSG and Amor 
criteria, even after adding “sacroiliitis on MRI” to the latter. The peripheral criteria with 
sensitivity of 77.8% and specificity of 82.8% are also promising for use in clinical practice 
[Rudwaleit, 2010a, 2010b]. The ASAS criteria have been developed as classification criteria 
but they are likely be useful as diagnostic criteria, especially in patients with non-radiographic 
axial SpA at an outpatient rheumatology clinic [van den Berg & van der Heijde, 2010]. This 
may help to make an early diagnosis and prevent the current diagnostic delay, described as 5 
to 10 years between the first occurrence of symptoms and an AS diagnosis [Feldtkeller et al., 
2003; Haibel et al., 2007]. It prevents unnecessary diagnostic tests and more importantly 
DISCUSSION AND CONCLUSIONS 
  
 
183 
 
makes it possible to commence more effective therapies earlier. This is crucial as at early 
disease stages, even those without definite radiologic sacroiliitis, can suffer as much pain and 
have as high a disease activity as patients with established AS [Rudwaleit et al., 2009a]. 
Therefore, it’s important to consider all patients with SpA with predominantly axial 
involvement irrespective of the presence or absence of radiographic changes as belonging to 
one disease continuum [Rudwaleit, 2005]. Despite all these advantages with the new ASAS 
criteria, one of the major reasons for diagnosis delay is a low awareness of AS among 
physicians in primary care [Sieper, 2009]. In this particular setting, several concerns have 
been raised regarding the use of ASAS criteria for diagnostic purposes [van den Berg & van 
der Heijde, 2010]. Thus current diagnosis of AS and SpA still relies on clinical and imaging 
parameters that may be relatively complex for general use in primary care. Screening 
parameters for an early referral of AS patients, easy to apply by the non-specialist, sensitive, 
specific and not too expensive, should be identified. For the rheumatology community this 
represents a great challenge. Expression studies can identify a small number of genes whose 
expression profile might serve as cost effective set of surrogate biomarkers for AS.  
One study has identified a small number of genes whose expression profile might serve as a 
cost-effective set of surrogate biomarkers for AS and uSpA [Gu et al., 2009]. In this PBMC-
based microarray study, all included patients fulfilled Calin criteria for inflammatory back 
pain and were taking NSAIDs and/or SSZ. They concluded that the overall gene expression 
was higher in uSpA than in AS patients and identified a member of the family of RGS1 as the 
most promising biomarker for uSpA and AS, with this gene more highly expressed in SpA 
than in AS. They demonstrated a receiver operating characteristic (ROC) area under the curve 
(AUC) range between 0.93-0.99. Biomarkers with ROC AUC 0.8-1.0 are usually considered 
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to be useful in clinical practice [Rao, 2003]. To evaluate arthritis related factors that might 
enhance RGS1 expression, a panel of 25 cytokines and chemokines on a monocyte derived 
human cell line were used. The 2 strongest activators of RGS1 expression were TNFα and IL-
17. However, in order to be implemented in clinical practice further studies are clearly 
required. It requires a multicenter, multi-ethnic validation but also comparison with results 
obtained through MRI and the new ASAS classification criteria. There are several other 
concerns. This gene was differentially expressed between AS patients and healthy controls, in 
another microarray study PBMC based [Duan et al., 2010], but contrary to the first study it 
was underexpressed. Finally, it wasn’t identified as differentially expressed in a recent 
published study from a well defined population of Portuguese ethnicity background 
[Pimentel-Santos et al., 2011]. These distinct results reinforce the need for larger studies 
involving different ethnic groups.  
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3.3.6. Gene expression changes after anti-TNFα therapy 
 
Biomarkers that allow quantitative assessment of treatment response have great potential in 
clinical practice. They enable appropriate choice of therapy, drug dosage to maximize effect 
and minimize toxicity, and monitor disease outcomes representing the foundation of 
evidence-based medicine [de Vlam, 2010]. The introduction of biologic therapies targeting 
TNFα (infliximab, etanercept, adalimumab, golimumab) has changed clinical practice with 
several benefits regarding clinical management and prognosis. Additionally, the scientific 
community is waiting for the market introduction of new biological treatments with new 
targets in the near future. Identification of markers of treatment response would be of great 
clinical benefit by facilitating better targeting of these treatments to those most likely to 
respond, and potentially significantly reduce treatment costs by minimizing use of these 
expensive agents in patients unlikely to respond.  
Until now the Visual Analogue Scale (VAS) pain, VAS general health, BASDAI, 
inflammatory parameters and composite response criteria are used to evaluate treatment effect 
in AS. ASAS defined and validated three levels of response: ASAS20, ASAS40, and ASAS 
partial remission, for patients treated with non-steroidal anti-inflammatory drugs and TNFα 
blockade [Anderson et al., 2001]. The recent introduction of the ASDAS criteria [van der 
Heijde et al., 2009] seems to be a highly discriminatory instrument for assessing AS disease 
activity and monitoring changes in disease and is finding good use in clinical practice. 
However all these criteria aren’t predictors of response to therapy and rely on subjective self-
evaluation and are not free from disease-unrelated influences, so biomarkers with high 
sensitivity and specificity for treatment response are highly desirable.  
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Current markers of response such shorter disease duration, HLA-B27 carriage, elevation of 
acute phase reactants (CRP), and marked spinal inflammation, as shown by MRI, may be 
predictors of good response; conversely, longer disease duration, structural damage and poor 
function may be predictors of poor- or non-response [Rudwaleit et al., 2004, 2008]. Data from 
the British Society of Rheumatology Biologics Register has shown raised inflammatory 
markers at the start of therapy predicted a greater improvement in disease activity [Lord et al., 
2010]. Predictors of improvement in function, measured using the BASFI, have shown a 
strong association with gender (significantly greater improvement in women) and concurrent 
disease-modifying antirheumatic drugs (DMARDs) therapy [Lord et al, 2010]. Finally, 
prevention of damage is another important outcome of therapy. Slow radiographic 
progression of the disease and the relatively small fraction of patients progressing over a 
period of 2-3 years make radiographic evaluation less sensitive for damage evaluation. 
However, the major predictor of progression is previous existing radiographic damage. While 
it is clear that anti-TNFα agents have a structural benefit in inflammation-mediated resorptive 
damage as indicated by changes in bone and cartilage metabolism, an effect on radiographic 
progression remains to be demonstrated in AS [de Vlam, 2010]. A study of the relationship of 
biomarker levels, disease activity and the spinal inflammation detected by MRI was 
performed in patients with AS receiving Infliximab over a 24 week period. Early reductions 
in IL-6 (by week 2) but not CRP or Vascular endothelial growth factor (VEGF), were 
significantly associated with reductions in MRI activity and BASDAI scores by week 24 in 
the infliximab group [Visvanathan et al., 2008]. However the structural changes of this effect 
are not known. 
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Gene expression profiling constitutes a widely available and promising technology to identify 
treatment-associated changes. In two recent studies it was demonstrated that anti-TNF α 
treatment leads to significant alteration of gene expression and protein profiles, supporting the 
use of systematic gene expression and proteomic analysis to shed new light on pathogenic 
pathways with importance in the chronic inflammation of AS [Haroon et al., 2010; Grcevic et 
al., 2010]. Anti-TNFα therapy induced a rapid change in the expression profile within 2 
weeks in AS patients with down-regulation of lymphotoxins exhibiting inducible expression 
and competing with herpes simplex virus glycoprotein D for herpesvirus entry mediator, a 
receptor expressed by T lymphocytes (LIGHT), interferon α receptor 1 (IFNAR1), interleukin 
17 receptor (IL17R) and erythropoietin receptor (EPOR) genes. LIGHT, a member of the TNF 
superfamily, was the most significantly down-regulated gene and serum soluble LIGHT levels 
correlate well with other inflammatory markers such as, CRP and ESR. However, no 
significant differences between responders and non-responders were observed in either 
LIGHT mRNA expression or LIGHT serum levels. A time gap between changes in 
inflammatory mediators and improvements in subjective disease severity scoring metrics may 
explain these findings [Haroon et al., 2010]. Although these results are interesting more 
studies are needed for validation. Another study using peripheral blood expression profiles 
based on PBMCs cells assessed several bone-regulatory factors as potential discriminators of 
different forms of arthritis, disease activity and therapy responsiveness [Grcevic et al., 2010]. 
ROC curve analysis suggested higher expression of Runx2 was a potential molecular maker 
for AS. Although no increased gene expression of BMP4 or LIGHT in AS patients compared 
with healthy controls were seen, higher expression was evident in AS patients resistant to 
conventional therapy. Thus LIGHT might be considered an interesting biomarker to consider 
in future studies.  
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Another marker which must be considered for a treatment-response marker is the CX3CL1-
CC3CR1 complex. In RA, CX3CL1 levels decline in patients showing a clinical response to 
infliximab treatment. Moreover, patients with active RA who did not show a clinical response 
to infliximab showed higher basal CX3CL1 levels than those who did [Odai et al., 2009]. 
These results suggest that the CX3CL1-CX3CR1 in patients with active RA may be sensitive 
to anti-TNFα therapy and confirm that CX3CL1 plays a crucial role in the pathogenesis of 
RA, although further investigations are required. These results suggest that CX3CL1-
CX3CR1 may be also relevant in AS process. This is further supported with the 
underexpression of this gene in AS patients [Pimentel-Santos et al., 2011]. 
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4. FINAL REMARKS 
The present research work made it possible to characterize AS in Portugal. The key-findings 
were: higher prevalence in males than in females (1.6:1); eight years delay from onset of 
symptoms and diagnosis; predominant axial involvement; AAU as the main extra-articular 
manifestation; high activity and severity of disease (BASDAI, BASFI and BASMI scores >4); 
widespread use of NSAIDs; low prescription of anti-TNFα agents; and low/moderate 
positivity for HLA-B27. 
The validation of Bath indices (BASDAI, BASFI, BASMI and BASG) in Portuguese version, 
was relevant for proper monitoring of patients. These indices were widespread and are 
currently being used as a standard. 
The newly defined BASDAI, BASFI, BASMI, and mSASSS charts for Portuguese patients   
allow for both comparisons of Portuguese patients to other ethnic groups and to monitor 
national patients over different periods of time. In a near future, proper validation of these 
charts will also allow to use them on an individual basis, meaning that patients may be 
monitored conviniently in clinical practice in a supplementary way. 
Genetic studies performed in Portugal validated genes that have also been previously 
identified in others ethnic groups; despite the relevance of MHC on AS susceptibility, 
primarily related to the HLA-B27, others non-MHC genes have been implied, such as ERAP1 
and IL23R.  Furthermore, new genes with interest in AS susceptibility and in new 
therapeutical targetting were also documented. The identification of one TNFSF8 
polymorphism in French population, then validated in the Portuguese and Belgian 
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populations, constitutes a new potential interesting finding to be confirmed in future studies. 
This research identified two HLA-B27 haplotypes, A*02/B*27/Cw*02/DRB1*01/DQB1*05 
confering susceptibility to AS, and A*02/B*27/Cw*01/DRB1*08/DQB1*04 providing 
protection in terms of disease activity, functional and radiological repercussion. Finally, 
validation of gene expression signature of AS from whole blood opens new and exciting 
perspectives into selecting highly discriminant biomarkers. 
From a research point of view, the present genetic identification also pointed out sound 
pathophysiologic pathways for disease initiation and progression. 
Adding the most relevant genetic markers to clinical and imagiologic parameters may yield 
diagnostic methods not only much more robust and specific but also more adapted to each 
patient – the final challenge in the quest of personalized medicine. 
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5. FUTURE PERSPECTIVES 
A recent and huge technology progress in the present field of research has been encompassed 
with great enthusiasm for the numerous discoveries achieved.  
There is now convincing evidence that AS assumes different patterns, clinically and 
genetically, according to ethnic groups considered. It was therefore mandatory to obtain data 
from Portuguese population.  
Future work in Portuguese context should be two-folded and aim at: 
a) Collecting new data from patients involved in the 2007 study; creating a cohort will 
enable to conduct prospective studies; 
b) Enlarging the database by enrolling further rheumatologic centres as to ascertain a 
higher results’ reliability. This last future goal is vital to obtain sound conclusions, to 
compare different ethnicities worldwide, and ultimately participate in international 
study consortia. 
During the current study, new research goals and questions have arisen. It is important to 
validate the charts for BASDAI, BASFI, BASMI, and mSASSS and assess their applicability 
on an individual basis. The analysis of AS economic burden in national population is yet 
another relevant aspect to complete. How does time influence the disease? It will be 
undoubtly interesting to compare current data with future information harvested after a five-
year period (2007-2012). In addition, next future work includes:  
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a) Population stratification into different subgroups according to relevant phenotypic 
characteristics;  
b) Sellect the most significant gene variants associated with AS susceptibility, 
proceed with functional analysis (animal models and/or cellular lineage 
experimenting) and study the influence of specific genes on phenotypic 
characteristics; 
c) Promote studies to screen patients and controls with different methodologies - 
RNA microarray, proteomic, and epigenetic studies - and thereafter try to integrate 
results. This could be an interesting means of identifying the most relevant 
“players” in pathophysiologic pathways of disease. 
As an ultimate goal, one might expect to establish an algorithm with clinical, imaging, and 
genetic data input to determine disease presence at an early stage, implement treatment as 
soon as possible and, therefore, improve long term prognosis. 
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7. ANNEXES  
ANNEXE I - RESUMO ALARGADO EM PORTUGUÊS 
 
1. INTRODUÇÃO 
A Espondilite Anquilosante (EA) é a doença de referência dentro do grupo das 
espondilartrites seronegativas (SpA), no qual se incluem também as artrites associadas a 
doenças intestinais inflamatórias (IBD), a artrite psoriásica, as artrites associadas a uveíte 
anterior aguda (AAU), as artrites reativas e as espondilartrites indiferenciadas (uSpA) 
[Rudwaleit et al., 2009a; 2010a; 2010b]. Estas doenças partilham diversas características 
como o envolvimento articular (axial e/ou periférico), o envolvimento extra-articular 
(entesopático e específico de órgão), a seronegatividade para o fator reumatoide e a forte 
associação ao HLA-B27 [Dougados et al., 1991; Calin & Taurog, 1998]. Neste contexto, a 
dor lombar inflamatória representa o "sintoma chave", a neo-formação óssea, traduzida pelo 
aparecimento de sindesmofitos conducentes à anquilose, a “imagem de marca” e a inflamação 
das entesis a "alteração histopatológica" característica da doença [Benjamin & McGonagle, 
2001]. 
A sua incidência e prevalência tendem a espelhar a prevalência do HLA-B27 [Khan, 1996]. 
Entre adultos positivos para a presença de HLA-B27, a prevalência de SpA foi estimada em 
4.5% e a de EA em 1.6%, [Benevolenskaya et al., 1996]. Nos Caucasianos, onde a 
positividade para o HLA-B27 é de 8%, a prevalência das SpA é de 1.3% e da EA oscila entre 
0.2-0.9% [Braun et al., 1998]. Em Portugal, estimou-se uma prevalência de 0.6% para a EA 
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[ONDoR, 2003-2005]. Assim, as SpA como um todo, e a EA em particular, encontram-se 
entre as formas mais frequentes de artrite.  
A incidência da EA tem também sido estudada em várias populações, registando-se algumas 
discrepâncias. Valores similares de 6,4; 6,9; 7.26; 7.3 por 100,000 pessoas/ano foram 
estimados nas populações da República Checa [Hanova et al., 2010], da Finlândia 
[Kaipiainen-Seppanen et al., 1997], da Noruega [Bakland et al., 2005] e de Rochester-EUA 
[Carbone et al., 1992], respetivamente. Na população da Grécia porém, a incidência parece 
ser significativamente mais baixa (1,5 por 100,000) [Alamanos et al., 2004]. Apesar da 
dificuldade em se avaliar de forma exacta a incidência e a prevalência da EA, devido à 
heterogeneidade étnica das populações, à dificuldade na aplicação dos critérios de diagnóstico 
e à natureza transitória de alguns sintomas [Reveille, 2011], parece haver em termos globais, 
uma relativa estabilidade destes parâmetros, pelo menos nos anos mais recentes [Gabriel & 
Michaud, 2009]. 
Em termos clínicos, a EA afeta tipicamente indivíduos jovens, iniciando-se os primeiros 
sintomas antes dos 30 anos em 80% e após os 45anos, em menos de 5% dos doentes 
[Feldtkeller et al., 2003]. Os homens tendem a ser mais frequentemente afetados que as 
mulheres, sendo no entanto, as proporções descritas variáveis oscilando de 2:1 [Feldtkeller et 
al., 2003, Brunner et al., 2002], 3:1 [Lee et al., 2007] até 6-8:1, como descritas em algumas 
populações Asiáticas [Lee et al., 2002; Zeng et al., 2003; Jung et al., 2010]. O mecanismo 
exacto subjacente a estas diferenças não é conhecido, mas o fator género parece exercer 
influência nas manifestações clínicas e no próprio prognóstico da doença. 
No espetro dos sintomas incluem-se a dor lombar inflamatória e/ou a oligoartrite periférica 
assimétrica (com envolvimento predominante dos membros inferiores), a entesite e o 
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envolvimento específico de órgão. A AAU, a psoríase e a doença inflamatória crónica do 
intestino são manifestações frequentes contrariamente ao envolvimento pulmonar, renal, 
neurológico e cardíaco [Braun & Sieper, 2007]. É importante, no entanto, referir que de 
acordo com vários estudos realizados na Europa e na Ásia, os doentes com EA têm maior 
prevalência de co-morbilidades comparativamente com a população saudável [Bremander et 
al., 2011]. Em Taiwan, foi documentado um aumento do risco de doença cardiovascular, 
neurológica, pulmonar, gastrointestinal, endócrina, hematológica e mental. A hipertensão 
(16.4%), a úlcera péptica (13.9%) e as cefaleias (10.2%) assumem-se como as complicações 
mais prevalentes [Kang et al., 2010]. O risco aumentado para doença cardiovascular tem sido 
um achado consistente, estando provavelmente relacionado com o processo de inflamação 
crónica e com a elevada prevalência de fatores risco cardiovasculares nestes doentes [Boonen 
et al., 2002; Bakland et al., 2011; Mathieu et al., 2010].  
A EA associa-se ainda a um aumento da mortalidade de 50% comparativamente com 
indivíduos saudáveis, do mesmo sexo e idade [Boonen et al., 2002]. Um estudo recente, 
baseado na avaliação de índices de mortalidade estandardizada, mostrou porém que o risco só 
se encontra significativamente aumentado entre os doentes do sexo masculino [Bakland et al., 
2011]. Estes apresentam também mais alterações estruturais (incluindo a coluna de bamboo), 
valores mais baixos de densidade mineral óssea [Karberg et al., 2005] e maior número de 
fraturas [Cooper et al., 1994], o que pode contribuir para uma cifose mais grave [Vosse et al., 
2006], comparativamente com os doentes do sexo feminino. Torna-se assim evidente que é 
importante avaliar de forma sistemática, o envolvimento articular e sistémico em cada 
indivíduo, para pôr em evidência o real impacto da doença, para o doente e para a sociedade.  
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Neste contexto, compreende-se facilmente que a EA possa levar a uma deterioração da função 
física e da qualidade de vida (QoL), condicionando um aumento da incapacidade para o 
trabalho e paralelamente, do consumo de serviços de saúde. Para se pôr em evidência o 
impacto da doença, efetuaram-se comparações entre doentes e a população geral [Ware, 
2000], usando medidas genéricas de QoL, como o Medical Outcomes Study Short Form-36 
(SF-36) [Guyatt et al., 1993]. Em diversos estudos efectuados, confirmou-se que a EA 
condiciona uma redução significativa da QoL comparativamente à população geral, o que se 
deve essencialmente ao compromisso dos domínios físicos (e em menor escala dos domínios 
da esfera psicossocial) [Dagfinrud et al., 2004; Davis et al., 2005; Singh & Strand, 2009]. Isto 
significa que o componente físico será o principal determinante da morbilidade associada à 
EA. Como muitos dos fatores implicados - gravidade e duração da doença, resposta à 
terapêutica e efeitos adversos, co-morbilidades, fatores socioeconómicos e acesso aos serviços 
de saúde - são fatores modificáveis, é de supor que intervenções específicas possam melhorar 
a função e a QoL destes doentes [Singh & Strand, 2009].  
Foram descritos elevados níveis de incapacidade para o trabalho com grande impacto na 
produtividade e nos custos sociais da doença [Boonen et al., 2002]. Na Holanda, dentro do 
grupo de doentes com EA, a percentagem de trabalhadores é 11% mais baixa e os níveis de 
incapacidade para o trabalho 15% mais elevados que na população em geral. No subgrupo de 
doentes com trabalho remunerado o número médio de dias de baixa relacionados com a EA 
foi de 10 dias/ano por doente [Boonen et al., 2001].  
Em termos de utilização de serviços de saúde, os resultados de alguns estudos Europeus, 
apontam para um consumo entre 1,4-4,0 consultas gerais e 1,7-2,8 consultas de 
especialidade/ano devido a problemas relacionados com a EA [Boonen et al, 2003a, 2003b, 
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2005; Verstappen et al., 2007]. Resultados semelhantes foram obtidos nos EUA com valores 
superiores a 2,1, para consultas gerais e de especialidade/ano [Ward, 2002]. Outros estudos, 
ao utilizarem bases de dados administrativas, do Canadá [Kobelt et al., 2006] e da Alemanha 
[Zink et al., 2006], apontam porém para consumos de 16-18 consultas gerais e de 3,7-4,2 
consultas de reumatologia/ano. Estes resultados não devem ser extrapoláveis pois existem 
múltiplos fatores que podem influenciar os resultados obtidos em cada país - o próprio 
sistema de saúde, as características das populações estudadas, as características dos doentes 
(incluindo a presença de co-morbilidades médicas e gravidade da doença) e os métodos de 
determinação da utilização dos cuidados de saúde. Independentemente destes aspetos, os 
vários estudos documentam um aumento da utilização dos serviços de saúde, havendo 
múltiplas razões para isso: 
a) A utilização dos cuidados primários motivada pelos sintomas diretamente 
relacionados com a SpA/EA (dor lombar, dor articular, entesite) e/ou a presença de 
co-morbilidades e/ou relacionado com complicações associadas ao tratamento;  
b) Recurso a cirurgias por problemas diretamente relacionados com SpA/EA (ex. 
artroplastia da anca ou joelho) e/ou relacionadas com situações de co-morbilidade; 
c) Recurso a consultas de reumatologia refletindo o normal seguimento dos 
doentes para ajuste e monitorização da terapêutica;  
d) Recurso a consultas de outras especialidades como gastrenterologia, nefrologia 
e cardiologia, por problemas relacionados com a própria SpA/EA ou complicações 
terapêuticas. 
Neste âmbito importa também analisar o impacto da EA em termos de custos. Os custos totais 
anuais ascendem a $6,720 dólares (dados de 1999; mediana de $1,495) dos quais 73,6% 
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representem custos indiretos e 26,4% custos diretos. Curiosamente, apenas 39% dos doentes 
contribuem para os custos indiretos [Ward, 2002] sendo a incapacidade funcional o principal 
determinante desses custos. A probabilidade de ter um custo total elevado aumenta 3 vezes 
por cada elevação de 1 ponto no “Health Assessment Questionnaire disability index modified 
for the spondylarthropathies” (HAQ-S; oscila entre 0-3) [Ward, 2002]. Assim, as 
intervenções que possam contribuir para manter ou melhorar a capacidade funcional dos 
doentes poderão ter um grande potencial para reduzir os custos associados à EA. As co-
morbilidades poderão também exercer influência mas são necessários mais estudos para 
avaliar o seu impacto, em termos de número e de gravidade, no consumo de recursos e custos 
associados [Boonen et al., 2002]. 
Tendo em consideração os aspetos da prevalência, da progressiva e irreversível anquilose das 
articulações afetadas, das co-morbilidades e do impacto socioeconómico da doença parece 
evidente que o diagnóstico numa fase inicial e a introdução atempada de um tratamento 
efetivo deverão exercer uma influência positiva no prognóstico da doença - o que representa 
o atual paradigma na abordagem da doença. Vários estudos mostraram existir um atraso 
diagnóstico superior a 8 anos, entre o início dos sintomas e o diagnóstico, motivando um 
atraso do início da terapêutica [Feldtkeller et al., 2003]. Este é um período crítico para a 
ocorrência de dano estrutural. A resposta às diferentes terapêuticas é porém imprevisível, 
mesmo em doentes clinicamente semelhantes. 
A introdução de terapêuticas biológicas tendo como alvo o TNF alfa - infliximab, etanercept, 
adalimumab, golimumab – e a iminente introdução de outras com diferentes alvos 
terapêuticos, modificaram/-rão a prática clínica com prováveis benefícios no controlo da 
sintomatologia e provavelmente em termos de prognóstico. Os critérios para classificar 
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doentes com EA, nomeadamente os critérios modificados de Nova Iorque [van der Linden et 
al., 1984a], requerem a presença de sacroiliite radiológica. Foi estimado um período de 6 a 8 
anos entre o início da inflamação nas articulações SI e a sua possível deteção nas radiografias 
convencionais [Rudwaleit et al., 2005, 2009a; Bennett et al., 2008]. Embora desconheçamos a 
proporção de doentes com SpA que evoluem para EA, os doentes com SpA axial não-
radiográfica têm parâmetros de atividade de doença semelhante aos doentes com EA 
estabelecida em termos de sinais e sintomas [Rudwaleit et al., 2009a], pelo que se colocou a 
hipótese de que poderão corresponder a diferentes estádios da mesma doença [Rudwaleit et 
al., 2005]. Assumindo esta hipótese como verdadeira, os novos critérios ASAS para SpA 
axial, podem contribuir para uma mais rápida e precoce identificação da doença numa fase 
anterior ao aparecimento das alterações radiográficas.  
A avaliação da eficácia da terapêutica tem sido feita com recurso ao BASDAI 50 [Braun et 
al., 2003] e/ou critérios de melhoria ASAS [Anderson et al., 2001], embora se desconheça em 
que medida são realmente adequados para esse fim. A recente introdução do ASDAS revelou-
se como um instrumento muito útil para a prática clínica, pelo elevado poder discriminativo 
na avaliação da atividade da EA e na resposta à terapêutica [Lukas et al., 2009; van der Heijde 
et al., 2009; Machado et al., 2011]. Não tem, no entanto, qualquer papel como preditor de 
resposta à terapêutica.  
Neste contexto, a identificação de novos marcadores com maior poder discriminativo, 
passíveis de serem aplicados para se estabelecer o diagnóstico, o prognóstico e como 
preditores de resposta à terapêutica, assume grande relevância. Ao facilitar a abordagem do 
doente e simultaneamente ao possibilitar uma melhor adequação da terapêutica poderiam 
contribuir para uma racionalização dos custos.  
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Nos últimos anos, o progresso dos métodos de genotipagem e do desenho dos próprios 
estudos de investigação, revolucionaram o conhecimento das doenças comuns tendo tido 
grande impacto na EA. Um enorme salto foi dado entre 2007 e 2011 conhecendo-se 
atualmente 14 genes para além do HLA-B, associados à doença [Brown et al., 2010; Evans et 
al., 2011]. Dois estudos recentes, puseram ainda em evidência que o tratamento com anti-
TNF α leva a alterações significativas da expressão génica e no perfil proteico, o que faz com 
que estes métodos possam provavelmente contribuir para uma melhor compreensão dos 
mecanismos patogénicos envolvidos [Visvanathan et al., 2008; Haroon et al., 2010] bem 
como para a identificação de marcadores de resposta à terapêutica. Os marcadores atualmente 
disponíveis associados a favorável resposta à terapêutica são a idade jovem, a positividade 
para o HLA-B27, a elevação dos reagentes de fase aguda (CRP) e a presença de sinais de 
inflamação na RMN. De forma inversa, a idade avançada, a presença de alterações estruturais 
e de alterações funcionais são preditores de ausência ou má resposta [Rudwaleit et al., 2004, 
2008]. Embora sejam biomarcadores com significância estatística parece claro que novos 
biomarcadores mais discriminativos são necessários para serem usados na prática clínica. Este 
foi o grande desafio deste trabalho e representa um enorme desafio para o futuro próximo. 
Para a prática clínica, a integração de novos biomarcadores com os novos critérios de 
classificação e de monitorização poderá mostrar-se muito útil para clínicos, doentes e 
sociedade. 
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2. COMPONENTE CIENTÍFICA 
A realização deste projeto de investigação motivou a criação de um grupo de trabalho 
denominado COnhcer a Realidade PORtuguesa sobre Espondilite Anquilosante 
(CORPOREA). Nele participaram inúmeros médicos de vários centros de Reumatologia (e 
um de Fisiatria) nacionais - Centro Hospitalar de Lisboa Ocidental, Hospital de Egas Moniz 
EPE, Lisboa; Centro Hospitalar de Lisboa Norte, Hospital de Santa Maria EPE, Lisboa; 
Instituto Português de Reumatologia, Lisboa; Hospital Militar Principal, Lisboa; Hospital 
Curry Cabral EPE; Hospital Garcia de Orta EPE, Almada; Centro Hospitalar do Alto Minho, 
Hospital Conde de Bertiandos EPE, Ponte de Lima; Hospital de São Marcos, Braga; Hospital 
de Faro EPE, Faro; Centro Hospitalar Baixo Vouga, Hospital Infante D. Pedro EPE, Aveiro; 
Centro Hospitalar Oeste Norte, Centro Hospitalar das Caldas da Rainha EPE, Caldas da 
Rainha. Por se pretender reduzir possíveis fatores de enviezamento, relacionados com o 
recrutamento de doentes, não foram incluídos os centros de Reumatologia das regiões 
autónomas. Foram ainda estabelecidas parcerias nacionais (Instituto de Medicina Molecular, 
Faculdade de Medicina da Universidade de Lisboa) e internacionais (Diamantina Institute for 
Cancer, Immunology and Metabolic Medicine, Princess Alexandra Hospital, University of 
Queensland, Brisbane, Australia; Institut Cochin, Department of Immunology and INSERM, 
Paris, França), o que permitiu reunir as condições necessárias à realização dos vários tópicos 
do projecto.  
O envolvimento das múltiplas unidades nacionais, permitiu oferecer uma dimensão nacional 
ao projecto. Num período de 6 meses, uma equipa de médicos do Hospital Egas Moniz 
dirigiu-se periodicamente aos diversos centros para entrevistar, avaliar e colher amostras 
biológicas dos doentes recrutados em cada local. Foi assim constituída uma cohorte de 369 
ANNEXES 
  
 
238 
 
doentes, com o diagnóstico de EA de acordo com os critérios modificados de Nova Iorque, 
com idade superior a 18 anos, de ascendência Portuguesa até à segunda geração, que 
manifestaram a sua concordância em participar neste projeto de investigação, tendo para isso 
assinado de livre vontade o termo de responsabilidade. O projeto de investigação obteve o 
parecer favorável da Comissão de Ética do CHLO e de todos os estabecimentos hospitalares 
envolvidos. Paralelamente, recrutaram-se em diferentes locais, amostras biológicas de 
indivíduos saudáveis que constituíram o grupo de controle. Foram ainda selecionados de 
forma aleatória alguns indivíduos que integram a base nacional de dadores de medula óssea 
do Centro de Histocompatibilidade do Sul.  
Foram objetivos deste Projecto: 
a) Caracterização clínica e epidemiológica da EA em Portugal; 
b) Validação para língua Portuguesa dos principais índices de Bath; 
c) Criação de instrumentos para monitorização da doença; 
d) Identificação de biomarcadores com utilidade para o diagnóstico e avaliação 
prognóstica da doença. 
Os principais resultados do estudo efetuado serão sumariamente descritos nos tópicos 
seguintes, com referência aos artigos em que foram publicados. 
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2.1. INVESTIGAÇÃO CLÍNICA  
2.1.1. Versão Portuguesa dos Índices de Bath 
Pimentel-Santos FM, Pinto LT, Santos H, Barcelos A, Cunha I, Branco JC, Ferreira PL. Portuguese version of 
the bath indexes for ankylosing spondylitis patients: a cross-cultural adaptation and validation. Clin 
Rheumatol. 2012 Feb; 31(2): 341-6. 
 
Foram adaptados e validados para Português (falado em Portugal), o "The Bath Ankylosing 
Spondylitis Disease Activity Index" (BASDAI), o "The Bath Ankylosing Spondylitis 
Functional Index" (BASFI), o "The Bath Ankylosing Spondylitis Metrology Index" (BASMI) 
e o "The Bath Ankylosing Spondylitis Global Score" (BASG), que constituem índices 
frequentemente utilizados na avaliação dos doentes na prática clínica corrente. As versões 
Portuguesas destes índices encontram-se no Anexo II. Após tradução e retroversão dos 
questionários, foi feita a sua aplicação a 78 doentes, com o intuito de se avaliar a Consistência 
Interna, a Reprodutibilidade e a Validade dos mesmos. A Consistência Interna oscilou entre 
0,747 e 0,953. Os Coeficientes de Correlação obtidos na prova do teste-reteste foram de 
0,875/ 0,937/ 0,831/ 0,961 para o BASDAI, BASFI, BASMI e BASG, respetivamente. Todos 
os índices mostraram ser compreensíveis de acordo com a opinião expressa por um painel de 
doentes. Os vários aspetos da validade foram também assegurados. Este estudo teve como 
principal limitação a não inclusão de medidas de resposta ao tratamento, pelo que a 
determinação da sensibilidade à mudança não foi determinada. 
As versões Portuguesas destes índices mostraram possuir propriedades clinimétricas idênticas 
às versões originais e sobreponíveis às versões validadas para outros idiomas, pelo que 
ANNEXES 
  
 
240 
 
poderão ser utilizadas para a correta avaliação dos doentes, que usam o Português falado 
correntemente em Portugal, na prática clínica corrente ou para fins de investigação. 
2.1.2. Caracterização Clínica e Epidemiológica da EA em Portugal 
Pimentel-Santos FM, Mourão AF, Ribeiro C, Costa J, Santos H, Barcelos A, Pinto P, Godinho F, Cruz M, Sousa 
E, Santos RA, Rabiais S, Félix J, Fonseca JE, Guedes-Pinto H, Brown MA, Branco JC and CORPOREA Study 
Group. Spectrum of ankylosing spondylitis in Portugal. Development of BASDAI, BASFI, BASMI and 
mSASSS reference centile charts. Clin Rheumatol. 2012 Mar; 31(3): 447-54. 
 
No grupo total dos 369 doentes avaliados, 62,3% eram do sexo masculino conferindo um 
ratio masculino:feminino de 1,6:1. A idade média±(DP) do grupo era de 45,4±13,2 anos 
(oscilando entre 20-79 anos) com uma duração média de doença de 11,4±10,5 anos (oscilando 
entre 0-46 anos). A idade média de início dos sintomas foi de 26,5±10,8 anos e a idade média 
do diagnóstico de 34,1±13,4 anos [o início juvenil (idade < 16 anos) foi reportado em 39  
(10.6%) dos casos e o início tardio (idade > 40 anos) em 37 (10%)], o que denota um atraso 
no estabelecimento do diagnóstico de 7,6±9,0 anos [inferior a 1 ano em 51 (13.8%) casos e 
superior a 10 anos em 86 (23.3%)]. Atrasos diagnósticos idênticos foram descritos noutros 
países [Feldtkeller et al., 2003]. Reportaram história familiar em primeiro grau 17.6% dos 
doentes. A dor lombar (42,3%) foi a manifestação inicial mais comum. No momento da 
avaliação, 49,9% apresentavam um envolvimento axial, 2.4% um envolvimento periférico, 
40.9% misto e 7.1% entesopático isolado. Referiram manifestações extra-articulares 35,2% 
dos doentes tendo sido a uveíte anterior aguda (33.6%) a mais comum. A psoríase (6.2%), a 
doença intestinal inflamatória (2.4%), a doença pulmonar (1.4%), a doença cardíaca (1.1%) e 
a renal (0.3%) foram descritas de forma menos frequente. 
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A avaliação global da doença efetuada pelo doente e pelo médico (4.7 vs 2.6, p<0.001) 
mostraram ser significativamente diferentes, não considerando os médicos a doença tão grave 
quanto os doentes. O valor médio do BASDAI foi de 4,2±2,3, do BASFI de 4,1±2,7, do 
BASMI 4,0±2,5 e do mSASSS 20,9±23,1.  
A abordagem terapêutica foi também analisada, considerando-se para esse efeito, a medicação 
efetuada no momento da avaliação. A maioria dos doentes encontrava-se sob terapêutica com 
AINE’s (79.1%), de forma contínua ou intermitente e uma pequena mas significativa 
proporção, tomava corticoides (17.6%). Estes resultados confirmam valores encontrados, em 
estudos prévios, na nossa população [Sousa et al., 2008]. Estavam sob terapêutica DMARDs 
48.5% dos doentes, sendo a SSZ (30.9%) o mais utilizado, seguida pelo MTX (8.4%); a 
associação SSZ e MTX eram cumpridas por 6% dos doentes. Sob terapêutica anti-TNF-α 
encontravam-se 22% dos doentes. Este valor sendo semelhante ao descrito noutras populações 
[Collantes et al., 2007; Strömbeck et al., 2009], é inferior ao estimado por vários líderes de 
opinião (30-49%) [Landewe et al., 2004; Pham et al., 2006] como sendo a percentagem de 
doentes que carecem deste tipo de terapêutica. A correlação positiva entre os valores de 
BASMI e a terapêutica anti-TNFα (p=0.024) pode, por outro lado, ser uma evidência indireta 
de que estes fármacos são iniciados tardiamente no curso da doença. 
Tal como referido noutras populações, a EA afeta mais frequentemente os indivíduos do sexo 
masculino. A idade de início de sintomas, a idade de diagnóstico e o atraso no diagnóstico são 
porém, idênticas nos dois sexos, na nossa população. Verificou-se, no entanto, que nas 
mulheres os valores médios do BASDAI e do BASFI eram 1,2 e 0,7 pontos superiores, 
respetivamente, e que os do BASMI e do mSASSS eram 0,8 e 17,6 pontos inferiores, 
respetivamente, sendo as diferenças estatisticamente significativas. Estes resultados parecem 
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apontar para que a doença tenha uma maior atividade (BASDAI) e maior repercussão 
funcional (BASFI), com melhor metrologia (BASMI) e melhor compromisso radiológico 
(mSASSS) nas mulheres comparativamente aos homens. Estas diferenças são consistentes 
quando os resultados são avaliados como um todo ou, quando diferentes períodos de tempo, 
são considerados. Esta noção é reforçada pela análise das tabelas de percentis elaboradas para 
os índices de BASDAI, BASFI, BASMI e mSASSS, com base em “generalized linear 
models”. Apesar das diferentes metodologias estatísticas utilizadas, da pequena dimensão da 
amostra, dos diferentes ratios sexo masculino:femininos, os resultados da população 
Portuguesa foram muito semelhantes aos reportados na população Inglesa [Taylor et al., 
1998]. Estes gráficos fornecem informação sobre a atividade da doença e o seu impacto em 
termos de repercussão funcional, metrológica e radiológica ao longo do tempo. Podem assim, 
permitir comparar uma mesma população em diferentes momentos ou diferentes populações. 
Este tipo de representação visual pode ainda, ao contribuir para uma melhor compreensão da 
doença, aumentar a compliance do doente à intervenção proposta. A sua aplicação numa base 
individual na prática clínica corrente carece, no entanto, de uma adequada validação o que 
implica a recolha prospetiva de dados.  
Em conclusão, neste tópico procedeu-se à validação para língua Portuguesa dos principais 
índices de Bath utilizados na clínica. Paralelamente, promoveu-se a caracterização clínica e 
demográfica dos doentes com EA em Portugal. O desenvolvimento das tabelas de percentis 
constitui de forma adicional, um instrumento útil para avaliar modificações do padrão da 
doença ao longo do tempo e/ou em resposta às intervenções terapêuticas efetuadas, bem como 
para estabelecer comparações com outros grupos populacionais. 
 
ANNEXES 
  
 
243 
 
 
2.2. ESTUDOS DE BASE GENÉTICA  
2.2.1. Estudos de Genes MHC (HLA classe I, II e III)  
Pimentel-Santos FM, Matos M, Ligeiro D, Mourão AF, Ribeiro C, Costa J, Santos H, Barcelos A, Pinto P, 
Godinho F, Cruz M, Sousa E, Santos RA, Fonseca JE, Trindade H, Guedes-Pinto H, Brown MA, Branco JC and 
CORPOREA Study Group. HLA Class I and II Associations of Ankylosing Spondylitis. (Submitted to J 
Rheumatol.) 
Sousa E, Caetano-Lopes J, Pinto P, Pimentel F, Teles J, Canhão H, Rodrigues A, Resende C, Mourão AF, 
Ribeiro C, Pinto TL, Rosa CM, da Silva JA, Branco J, Ventura F, Queiroz MV, Fonseca JE. Ankylosing 
spondylitis susceptibility and severity-contribution of TNF gene promoter polymorphisms at positions -
238 and-308. Ann N Y Acad Sci. 2009 Sep; 1173: 581-8. 
 
Na cohort Portuguesa, 285:355 (80.3%) dos doentes com EA eram HLA*B27 positivos. Este 
resultado é similar ao da Grécia (80.5%) [Alamanos et al., 2004], inferior ao de Espanha 
(94.3%) [Fernández-Sueiro et al., 2004] mas superior ao valor encontrado na Turquia (70%) 
[Gunal et al., 2008].  
Um grupo aleatório, de doentes HLA*B27 positivos (n=188) e de controlos (n=189) foram 
selecionados e genotipados para as classes I e II do HLA por PCR-SSOP. Os haplótipos 
estendidos foram estimados por Expectation Maximization algorithm usando o software 
Arlequin v3.11. As comparações caso-controlo foram feitas com tabelas de contingência para 
os loci e para os haplótipos estimados. As associações entre as características genéticas e 
fenotípicas foram efetuadas através de regressões lineares e logísticas binomiais usando o 
software Stata10.1.  
Na população Portuguesa não se encontraram associações dos loci HLA estudados (para além 
do HLA*B27) e a suscetibilidade para a doença. Esta situação contrasta com os resultados de 
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estudos prévios, em que vários alelos classe I e II foram descritos como associados, 
positivamente ou negativamente à doença. Na classe I, o HLA-B60 (B*40) e o HLA-B*14, 
foram descritos como alelos associados à suscetibilidade para a EA em populações 
Caucasianas [Robinson et al., 1989] e Africanas (Togo e Camarões) [Merino et al., 2005; 
Brown et al., 2008], respetivamente. O HLA-B*07 [Kchir et al., 2010] e o HLA-B*51, pelo 
contrário, parecem exercer proteção para a EA em várias populações Mediterrânicas [Hajjej et 
al., 2006; Kchir et al., 2010]. Na classe II, o HLA-DR*01 foi descrito como conferindo 
suscetibilidade para a EA, independentemente do HLA-B*27, na população Inglesa e 
Mexicana [Brown et al., 1998; Vargas-Alarcon et al., 2002], o HLA-DR*08 na Inglesa 
[Brown et al., 1998] e o HLA-DQ*02 na Espanhola [Sanmarti et al., 1987].  
Na população estudada identificaram-se porém, várias associações entre alelos e as 
características fenotípicas da doença. O HLA-B*18 associou-se a início da doença em idade 
jovem, o DQB1*02 a história familiar, o B*14, B*44, DRB1*08 a AAU, o B*14 e o DRB1*08 
a gravidade radiológica. Em contraste, o alelo DQB1*04 parece conferir proteção em termos 
de atividade e de repercussão funcional, metrológica e radiológica da doença. Nenhuma 
destas associações foi previamente reportada na literatura com exceção da associação entre 
HLA-DRB1*08 e AAU [Brown et al., 2008]. Os diferentes resultados obtidos nos vários 
estudos poderão ser atribuídos a diferentes metodologias e a diferenças étnicas existentes. 
Atendendo à densidade de genes e à frequência dos desequilíbrios de ligação nesta região a 
identificação de variantes realmente associadas à EA torna-se muito difícil. O estudo dos 
haplótipos pode facilitar a identificação dessas variantes pelo que se procedeu a essa análise. 
O haplótipo A*02/B*27/Cw*02/DRB1*01/DQB1*05 (p<0,0001; OR=39,06; CI 95% [2,34-
651]) foi o único identificado como sendo capaz de conferir suscetibilidade para a EA. Pelo 
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contrário, foram encontrados vários haplótipos associados às características fenotípicas da 
doença. A associação mais robusta estabeleceu-se com o 
A*02/B*27/Cw*01/DRB1*08/DQB1*04, que parece conferir proteção para a atividade e 
repercussão funcional e radiológica da doença. A inexistência na literatura de estudos 
semelhantes (envolvendo haplótipos estendidos) torna difícil estabelecer comparações com 
outras populações.  
O estudo efetuado sendo inovador apresenta algumas limitações relacionadas com a pequena 
dimensão da amostra e pela inclusão estrita de doentes HLA-B27 positivos. Os resultados 
obtidos carecem assim de confirmação em estudos futuros.  
Da parceria estabelecida com o Instituto de Medicina Molecular obtiveram-se novos dados 
relacionados com a avaliação da influência dos polimorfismos, nas posições -238 e -308, do 
promotor do gene TNF (classe III do HLA) na suscetibilidade e prognóstico da EA. Os SNPs 
foram analisados por "restriction fragment length polymorphisms " (RFLP) em doentes 
(n=141) e controlos (n=117). 
Constatou-se que os doentes com EA, apresentavam uma frequência do alelo A na posição -
238, menor (10%) que os controlos (18%), sugerindo um efeito protetor deste alelo na 
suscetibilidade para a doença (p<0.05). A frequência dos alelos na posição -308 foi 
semelhante nos dois grupos, doentes e controlos. Estes resultados eram independentes da 
positividade para o HLA-B27. De forma adicional, o genótipo -238 GA/AA associou-se a 
valores elevados de VS comparativamente ao -238 GG (45.7±28.8mm/1ª hora vs. 
20.2±15.3mm/1ª hora, p<0.05, respetivamente) e os doentes com genótipo -308 GA/AA 
tinham um início mais tardio da doença, comparativamente com os -308 GG (28±11 anos vs. 
24±9 anos, p<0,05, respetivamente). Na literatura, encontram-se vários estudos com foco em 
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polimorfismos nas posições, −308 (G/A) e −238 (G/A) do promotor do gene do TNF-α 
[Verjans et al., 1994; Fraile et al., 1998b; Hohler et al., 1998; Kaijzel et al., 1999; McGarry et 
al., 1999; Martinez-Borra et al., 2000; Milicic et al., 2000; Gonzalez et al., 2001; Vargas-
Alarcon et al., 2006; Shiau et al., 2007; Lu et al., 2008; Chatzikyriakidou et al., 2009; 
Nicknam et al., 2009; Sousa et al., 2009], com resultados discordantes. As pequenas 
dimensões das amostras, o insuficiente poder estatístico, a heterogeneidade clínica e as 
diferenças étnicas, têm sido apontados como possíveis fatores explicativos pelo que foram 
recentemente efetuadas duas meta-análises [Lee & Song, 2009; Li et al., 2010]. Em nenhuma 
delas se verificou associação entre os polimorfismos estudados e a suscetibilidade para a EA, 
quando se considerou o grupo total ou apenas os doentes HLA-B27 positivos.  
Em conclusão, estimou-se uma prevalência baixa/moderada de HLA-B*27 (80.3%) na 
população Portuguesa com EA. Foi descrito um haplótipo capaz de conferir suscetibilidade 
para a doença e outro que de forma consistente se associa a proteção, em termos de atividade 
e gravidade da doença. O estudo dos polimorfismos nas posições -238 e -308 do promotor do 
gene do TNF, apontou para que os mesmos exerçam uma pequena influência na 
susceibilidade e prognóstico da EA.  
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2.2.2. Estudos de Genes não-MHC (IL23R, ERAP1, ANKH, TNFSF)  
Pimentel-Santos FM, Ligeiro D, Matos M, Mourão AF, Sousa E, Pinto P, Ribeiro A, Sousa M, Barcelos A, 
Godinho F, Cruz M, Fonseca JE, Guedes-Pinto H, Trindade H, Evans DM, Brown MA, Branco JC. Association 
of IL23R and ERAP1 genes with ankylosing spondylitis in a Portuguese population. Clin Exp Rheumatol. 
2009;27(5):800-6. 
Pimentel-Santos FM, Ligeiro D, Matos M, Mourão AF, Sousa EV, Pinto P, Ribeiro A, Santos H, Barcelos A, 
Godinho F, Cruz M, Fonseca JE, Guedes-Pinto H, Trindade H, Brown MA, Branco JC and CORPOREA Study 
Group. ANKH and Susceptibility to and Severity of Ankylosing Spondylitis. J Rheumatol 2012;39(1):131-4.. 
Zinovieva E, Kadi A, Letourneur F, Cagnard N, Izac B, Vigier A, Said-Nahal R, Elewaut D, de Vlam K, 
Pimentel-Santos F, Chiocchia G, Breban M. Systematic candidate-gene investigations in the SPA2 locus 
(9q32) show an association between the gene TNFSF8 and susceptibility to spondyloarthritis. Arthritis 
Rheum. 2011;63(7):1853-9.  
 
A associação entre a EA e os genes, ERAP1 e IL23R, tinha sido recentemente reportada nas 
populações Norte-Americana e Inglesa, com riscos atribuídos de 25% e 9%, respetivamente 
[WTCCC/TASC, 2007]. Outros estudos prévios mostravam resultados contraditórios em 
relação ao gene ANKH [Tsui et al., 2005; Timms et al., 2007; Furuichi et al., 2008;].  
A associação da IL23R com a EA tinha sido replicada na população do Canadá [Rahman et 
al., 2008] e Espanhola [Rueda et al., 2008]. Outros estudos demonstraram ainda a associação 
dos SNPs da IL23R com a suscetibilidade para a doença de Crohn’s (CD) [Barrett et al., 
2008], psoríase [Cargill et al., 2007] e artrite psoriásica [Filer et al., 2008; Liu et al., 2008; 
Huffmeier et al., 2009], pelo que este gene parece conferir suscetibilidade para as 
espondilartrites sero-seronegativas como um todo e assim se pode explicar, pelo menos de 
forma parcial, a sua coocorrência. Em contraste, o ERAP1 parece conferir suscetibilidade de 
forma específica para a EA. O ANKH, apesar dos resultados contraditórios em termos de 
associação à EA, revestia-se de particular interesse porque ratinhos, com mutações com perda 
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de função do gene homólogo, ank, desenvolviam uma mineralização ectópica e uma anquilose 
óssea muito semelhante à da EA [Ho et al., 2000]. Em Humanos, a descrição de casos de 
condrocalcinose associados a mutações com ganho de função [Williams et al., 2002; Zhang et 
al., 2005] e de vários casos de espondiloartropatia numa família associados a homozigotia 
para uma mutação com perda de função do gene [Morava et al., 2010] reforçavam o interesse 
colocado neste gene. 
Neste contexto, pretendeu-se testar na população Portuguesa, a associação entre estes SNPs e 
a suscetibilidade para a doença e/ou a possível influência nas suas manifestações clínicas. A 
genotipagem das variantes alélicas da IL23R, ERAP1e ANKH foi realizada por "TaqMan 
allelic discrimination assays".  
Foram analisados 5 SNPs para o ERAP1, 1 para LN-PEP, 8 para a IL23R e 4 para o ANKH. 
Os SNPs rs27044 e rs30187 do ERAP1 e os rs1004819 e rs10889677 da IL23R mostraram 
significativa associação à doença. Confirmou-se assim a associação destes genes à doença na 
população Portuguesa, com riscos atribuídos de 9,7% e 11%, respetivamente. Não se 
verificou porém, associação com o SNP do LN-PEP, que flanqueia o ERAP1, e que tinha 
mostrado associação com a EA na população Inglesa [WTCCC, 2007]. Do mesmo modo, não 
se estabeleceu associação com nenhum dos 4 SNPs estudados do ANKH, sugerindo que este 
gene não deve ser um determinante major da suscetibilidade para a EA na nossa população. 
Finalmente, não se estabeleceu qualquer associação entre os diferentes SNPs estudados e as 
manifestações da doença como a idade de início de sintomas, BASDAI, BASFI, BASMI ou 
mSASSS.  
Em conclusão, confirmou-se que os genes da IL23R e do ERAP1 se encontram associados a 
suscetibilidade para a EA na população Portuguesa contribuindo com um risco de 11% e 
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9,7%, respetivamente, não se verificando o mesmo com o ANKH. Nenhum dos genes 
estudados pareceu exercer influência nas manifestações clínicas da doença.  
Em parceria com o INSERM foi possível contribuir para a validação da associação de um 
SNP do TNFSF8, recentemente descrito, e a EA.  
Na sequência de um "genome-wide linkage study" realizado na população Francesa foi 
identificada uma nova região associada a suscetibilidade para as SpA, no cromossoma 9q31-
34, denominado SPA2 [Miceli-Richard et al., 2004]. Esta região contém cerca de 85 genes, 
sendo curiosamente uma região paráloga do MHC, pelo que poderia conter outros fatores de 
suscetibilidade para as SpA [Said-Nahal et al., 2002]. Foram selecionados nove genes para 
um estudo adicional: ZNF618, A1L4R1_HUMAN (AF495724), AMBP, KIF12, ORM1, 
ORM2, C9ORF91, ENSESTG000000230601, e TNFSF8. Após ter sido efetuado o estudo de 
confirmação, apenas um SNP, rs3181357, localizado no gene TNFSF8 mostrou uma 
associação significativa com a doença. Este SNP foi posteriormente replicado usando doentes 
Portugueses e Belgas, tendo-se obtido um resultado muito significativo (OR=2.14; p= 
0.0001).  
O TNFSF8, pode ser assim considerado um gene candidato com relevância em termos 
funcionais. Codifica o CD30L (CD153), um ligando da superfamília TNF expresso em células 
CD4+ T ativadas, células apresentadoras de antigénio e neutrófilos, que interagem com o 
recetor CD30 em células Th efetoras ou de memória. A via de sinalização CD30L/CD30 tem 
um papel crítico na diferenciação de células Th17 in vitro e em in vivo [Sun et al., 2010]. É 
possível que o SNP do TNFSF8 descrito possa estar diretamente implicado, de forma isolada 
ou em combinação, com outros polimorfismos situados na mesma região, na predisposição 
para as SPA. Em alternativa, pode mascarar uma ou mais variantes não identificadas no 
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estudo, devido provavelmente a mecanismos de desequilíbrio de ligação, que exerçam esse 
efeito para suscetibilidade destas doenças. Algumas dúvidas se levantam no entanto, acerca 
do papel real desta variante pelo facto de não ter sido identificada nos GWAS efetuados no 
contexto do WTCCC/TASC.  
 
2.3. ESTUDOS DE EXPRESSÃO GÉNICA 
2.3.1. Análise pela tecnologia de microarrays 
Pimentel-Santos FM, Ligeiro D, Matos M, Mourão AF, Costa J, Santos H, Barcelos A, Godinho F, Pinto P, Cruz 
M, Fonseca JE, Guedes-Pinto H, Branco JC, Brown MA, Thomas GP. Whole blood transcriptional profiling 
in ankylosing spondylitis identifies novel candidate genes that might contribute to the inflammatory and 
tissue-destructive disease aspects. Arthritis Res Ther. 2011 Apr 7; 13(2): R57.  
 
Os estudos de associação genética permitiram identificar vários genes que contribuem para a 
suscetibilidade da EA mas este tipo de abordagem fornece pouca ou nenhuma informação 
relacionada com a alteração da atividade génica que ocorre durante a evolução da doença. Os 
perfis de transcrição criam uma “fotografia” da atividade celular num determinado momento e 
podem fornecer informação relevante sobre os mecanismos moleculares envolvidos na 
doença. O objetivo major na realização deste estudo foi tentar avaliar em que medida os perfis 
de expressão genómica, podem ser úteis na distinção entre doentes e controlos e na 
identificação de vias fisiopatológicas com relevância na patogenia da EA.  
No estudo realizado, de identificação e confirmação, foram envolvidos 18 doentes com EA e 
18 controlos emparelhados de acordo com o sexo e a idade (± 5 anos). Foram apenas 
incluídos doentes com BASDAI>4 e BASFI>4, medicados com AINE’s e/ou SSZ e excluídos 
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doentes sob anti-TNF, corticoides ou metotrexato. Para o estudo de validação foram 
envolvidos 78 doentes e 78 controlos emparelhados para sexo e idade. No estudo de 
identificação foram usados microarrays com recurso ao "Human HT-12 V3 Expression 
BeadChips"(Illumina, CA). No estudo de confirmação e validação recorreu-se a um método 
de PCR quantitativa em tempo real denominado "TaqMan Low Density Array Cards®" 
(TLDA). Foram identificados 221 genes diferencialmente expressos entre doentes e controlos 
com p<0,0005. Dos 47 genes selecionados para o estudo de validação (de acordo com os 
níveis de expressão, valor de p e relevância biológica), apenas 14 foram de facto validados. 
Entre eles, encontram-se genes com um papel bem documentado nos mecanismos de 
inflamação e outros que contribuem para uma melhor compreensão dos mecanismos 
envolvidos na progressão da EA. 
O PTPN1 e o DOCK10, estão ambos envolvidos nas ações mediadas pela IL4 [Paul & Ohara, 
1987], o que é de particular interesse uma vez que tem um papel relevante na patogenia da 
EA. A proteína tirosina fosfatase 1B (PTP1B) é uma enzima expressa de forma ubiquitaria, 
que regula negativamente múltiplas vias de sinalização dependentes da fosforilação da 
tirosina, incluindo a via de sinalização da IL4 [Lu et al., 2008]. A Dock10 é regulada pela IL4 
em células B [Yelo et al., 2008].  
A IL4 é um produto dos linfócitos T ativados, tendo efeitos de estimulação e de inibição das 
células B e T [Paul & Ohara, 1987, O'Garra et al., 1988; Jelinek & Lipsky, 1988; Rousset et 
al., 1988] e provavelmente também influencia a produção de células CD8+ T. Foi 
demonstrado recentemente que alguns subtipos destas células produzem ‘Th2’ citoquinas 
como a IL4, IL5 e IL10, embora a produção de citoquinas Th1, como o IFNγ seja a sua 
função habitual [Baek et al., 2008]. O potencial papel da IL4-na produção de células CD8+ T 
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não está completamente esclarecido mas os subtipos de células T, CD8+/TCR αβ+, com uma 
função regulatória (expressando CD25+, CTLA4+, Foxp3+, e sendo negativas para o IFNγ e 
perforina), foram previamente descritas no sangue periférico de doentes com EA [Jarvis et al., 
2005]. Estes resultados foram confirmados em estudos recentes que sugeriram um padrão de 
diferenciação alterado de células T, em doentes com EA e em saudáveis HLA-B27+ [Zhang et 
al., 2009]. É assim possível que esta predisposição para gerar células T, IL4+CD8+ possa ter 
algum efeito na patogenia das SpA [Jarvis et al., 2005; Zhang et al., 2009].  
O SPOCK2, também conhecido como Sparc/osteonectina, foi implicado, num estudo recente, 
como discriminante entre SpA e controlos [Sharma et al., 2009] e como exercendo um papel 
na regulação, produção, organização e manutenção da matriz cartilagínea [Hausser et al., 
2004; Gruber et al., 2005]. Neste processo, o TGFβ e o IFNγ, exercem efeitos antagónicos na 
regulação da colagenase (COL1A2); o TGF β ativa a enzima (via de sinalização do Smad) e o 
IFNγ inibe-a (via sinalização do Stat1). Curiosamente, a proteína produzida pelo EP300 faz 
parte do grupo de co-activadores de transcrição nuclear (nuclear p300/CBP transcriptional 
coactivators) que interagem com o Smad 3 e o Stat1a; da integração de sinais resulta a 
ativação ou inibição da COL1A2 [Ghosh et al., 2001]. A diminuição da expressão da EP300 
promove um estado pró-inflamatório [Ahmad et al., 2007] que contribui para a degradação da 
cartilagem. De forma adicional, a proteína p300, controlada pela fosfoinositido-3 cinase 
(PI3K)/AKT, é um importante co-ativador transcricional da Sox9 [Cheng et al., 2009], que 
modula a expressão do componente major da matriz extracelular - o agrecano. Finalmente, a 
EP300 parece estar associada à via da WNT, um mediador chave na formação óssea e das 
alterações da cartilagem que ocorrem na osteoartrose [Velasco et al., 2010]. 
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Em conclusão, foi validado um perfil de expressão génica para a EA a partir do sangue 
periférico e identificados genes candidatos que contribuem para a compreensão dos 
mecanismos inflamatórios e das alterações do metabolismo ósseo e cartilagíneo que ocorrem 
durante a evolução da doença. Novos estudos são porém necessários, para confirmação destes 
resultados. 
 
3. CONCLUSÕES 
Neste trabalho de investigação foi possível caracterizar a EA em Portugal. A maior 
prevalência no sexo masculino (1,6:1), o atraso diagnóstico de cerca de 8 anos, o 
envolvimento predominantemente axial, a uveíte como principal manifestação extra-articular, 
a elevada atividade e gravidade da doença traduzida por scores de BASDAI, BASFI e 
BASMI superiores a 4, a utilização generalizada de AINE’s e a baixa prescrição de agentes 
anti-TNFα, a positividade baixa/moderada para o HLA-B27, constituem, de forma sumária, os 
aspetos mais relevantes para a elaboração da imagem que a EA assume no nosso país.  
A validação para língua Portuguesa do BASDAI, BASFI, BASG e BASMI, índices 
indispensáveis para a monitorização adequada dos doentes foi alcançada tendo sido difundida 
e estando atualmente a ser utilizados de forma corrente. A elaboração de tabelas de percentis 
para o BASDAI, BASFI, BASMI e mSASSS, torna possível estabelecer comparações dos 
nossos doentes em diferentes momentos do tempo e com outros grupos populacionais. É 
possível que após uma validação adequada possam também vir a ser utilizados numa base 
individual, o que representaria um meio adicional, de fácil entendimento por parte dos 
doentes, para sua correta monitorização. 
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Os estudos de natureza genética efetuados contribuíram para uma melhor compreensão dos 
mecanismos fisiopatológicos envolvidos na EA e permitiram a identificação de potenciais 
biomarcadores com interesse na prática clínica, em termos de diagnóstico e prognóstico (e de 
adequação terapêutica). De facto, apesar do MHC conferir cerca de 50% da predisposição 
para a doença, em grande medida associada ao HLA-B27, outros genes foram identificados. 
Dos genes estudados na população Portuguesa, validaram-se algumas variantes do ERAP1 e 
da IL23R, como estando associados à EA. A identificação de um polimorfismo do TNFSF8, 
na população Francesa, posteriormente validado na população Portuguesa e Belga, constitui 
um novo dado que deverá ser confirmado em estudos futuros. Outro ponto de particular 
interesse constitui a identificação de um perfil de expressão, que diferencia os doentes com 
EA dos indivíduos saudáveis.  
Os recentes avanços no conhecimento contribuem para uma melhor compreensão dos 
mecanismos subjacentes ao desencadear da doença e sua evolução e a identificação de novos 
alvos terapêuticos que favorecem o desenvolvimento de novos fármacos. A integração futura 
de dados de natureza clínica, imagiológica e genética (com recurso a diferentes abordagens), 
poderá contribuir para a construção de algoritmos que permitam estabelecer mais facilmente o 
diagnóstico e prognóstico e favoreçam a seleção da terapêutica numa base individual, o que 
pode representar o início de uma medicina personalizada.  
Estudos envolvendo populações de diferentes etnias, de dimensões adequadas, permitindo 
análises de vários subgrupos de interesse permitirão complementar e validar a informação 
existente. Com base nos resultados encontrados vários estudos estão desenhados no sentido de 
contribuir de forma ativa para a estruturação do conhecimento nesta área. 
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ANNEXE II – VALIDATION OF BATH INDICES IN PORTUGUESE 
1. BASDAI 
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2. BASFI 
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3. BASG 
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